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Abstract 
Asthma is a disease characterized by chronic airway inflammation and by its long 
term irreversible remodeling. The enzymatic peroxidation of the arachidonic acid leads 
to the formation of bioactive eicosanoids, key mediators of bronchial inflammation and 
response modulation in the airways contributing to the pathophysiology of this disease. 
The present work aimed to develop an improved ultra-high pressure liquid 
chromatography (UHPLC)-based strategy to characterize biomarkers of lipid 
peroxidation: leukotrienes E4 (LTE4) and B4 (LTB4) and 11β-prostaglandin F2α 
(11βPGF2α), present in urine of asthmatic patients and healthy individuals (control 
group). A semi-automatic eVol®-microextraction by packed sorbent (MEPS) format was 
used to isolate the target analytes. Several experimental parameters with influence on this 
procedure and on the chromatographic resolution, were evaluated and optimized. The 
method was fully validated with compatible values under optimal extraction (R-AX 
sorbent, 3 conditioning-equilibration cycles with 250 µL of ACN-H2O at 0.1% FA, 10 
extract-discard cycles of 250 µL of sample at a pH of 5.1, elution with 2 times 50 µL of 
MeOH and concentration of the eluate until half of its volume) and chromatographic 
conditions (14-min analysis at a flow rate of 300 µL min-1 in an UHPLC-PDA equipped 
with a BEH C18 column).  
The developed method was successfully applied to the urine of asthmatic patients 
and healthy individuals. On average, the urine of asthmatic patients present significantly 
higher concentrations of 11βPGF2α (112.96 ng mL-1 vs 62.56 ng mL-1 in control group), 
LTE4 (1.27 ng mL-1 vs 0.89 ng mL-1 in control group) and LTB4 (1.39 ng mL-1 vs 0.76 ng 
mL-1 in control group). These results suggest the potential of the target eicosanoids on 
asthma diagnosis and on the follow-up of the therapeutic response, even though a larger 
and more extensive study will be necessary, using a bigger number of cases, to confirm 
the data obtained and to guarantee a greater robustness to the approach. 
 
 
 
 
Keywords: Asthma; biomarkers, 11β-Prostaglandin F2α; Leukotriene E4; Leukotriene B4; 
Microextraction by packed sorbent; Ultra-high pressure liquid chromatography.  
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Resumo 
A asma é uma doença caracterizada por inflamação crónica das vias aéreas e pela 
sua remodelação irreversível a longo prazo. A peroxidação enzimática do ácido 
araquidónico leva à formação de eicosanóides bioactivos, importantes mediadores da 
inflamação brônquica e da modulação da resposta nas vias aéreas contribuindo para a 
fisiopatologia desta doença. 
O presente trabalho teve como objectivo desenvolver uma estratégia aperfeiçoada 
baseada em cromatografia líquida de ultra pressão (UHPLC) para caracterizar 
biomarcadores da peroxidação enzimática: leucotrienos E4 (LTE4) e B4 (LTB4) e 11β-
prostaglandina F2a (11βPGF2α), presentes na urina de pacientes asmáticos e de indivíduos 
saudáveis. Foi utilizada uma microextracção por sorvente empacotado (MEPS) em modo 
semiautomático (eVol®) para isolar os analitos alvo. Foram avaliados e optimizados 
vários parâmetros experimentais com influência neste procedimento e na resolução 
cromatográfica. O método foi totalmente validado, com valores compatíveis em 
condições óptimas de extracção (sorvente R-AX, 3 ciclos de condicionamento-equilíbrio 
com 250 µL de ACN-H2O a 0,1% FA, com 10 ciclos de extracção-descarte de 250 µL de 
amostra a um pH de 5,1, eluição com 2×50 µL de MeOH e evaporação do eluato até 
metade do seu volume) e cromatográficas (análise de 14 minutos a uma taxa de fluxo de 
300 µL min-1 num UHPLC-PDA equipado com uma coluna BEH C18). 
O método desenvolvido foi aplicado com sucesso às amostras alvo. Em média, os 
pacientes asmáticos apresentaram concentrações significativamente mais elevadas de 
11βPGF2α (112,96 ng mL-1 vs 62,56 ng mL-1 em indivíduos saudáveis), LTE4 (1,27 ng 
mL-1 vs 0,89 ng mL-1 em indivíduos saudáveis) e LTB4 (1,39 ng mL-1 vs 0,76 ng mL-1 em 
indivíduos saudáveis). Estes resultados sugerem o potencial destes eicosanóides no 
diagnóstico da asma e no seguimento da resposta à terapêutica. Contudo, será necessário 
um estudo mais alargado e extensivo, usando um maior número de casos, para confirmar 
os dados obtidos e garantir uma maior robustez desta estratégia. 
 
 
 
Palavras-chave: Asma; 11β-Prostaglandina F2α; Leucotrieno E4; Leucotrieno B4; 
Microextracção por sorvente empacotado; Cromatografia líquida de ultra alta pressão.  
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Author’s note 
Asthma is a disease that affects millions of children all over the world. It affects 
not only patients but also their parents and the social system where they belong. Its 
diagnose is somehow difficult and require the expertise of a health technician. Usually it 
is performed based on symptomatic history, long-term follow-up, extensive differential 
diagnosis and by the response of the child to bronchodilator or anti-inflammatory 
medication. Therefore, the main motivation of this work was to contribute to the progress 
of asthma diagnose and precision medicine with the characterization of three biomarkers 
of this disease (LTE4 and LTB4 and 11βPGF2α) by means of two powerful analytical 
strategies, a sample preparation technique – microextraction by packed sorbent, and a 
separation and detection technique – ultra-high pressure liquid chromatography 
hyphenated to a photodiode array detector. 
This Master Dissertation was developed in two complementary parts, one 
theoretical and another experimental. Initially, the theoretical part of this Master 
Dissertation was meant to be done in only one chapter but, due to the relevance of both 
the pathological field and analytical chemistry, this information was deepened in terms 
of disease mechanisms and metabolomics, the first and second chapters respectively. 
Throughout the first chapter, the reader is guided through the “history” of asthma, a 
worldwide social and economic burden and the main biochemical mechanisms and 
pathways that characterizes this common disease. The second chapter describes the role 
of metabolomics, the potential of non-invasive sample procedures and the potential of the 
most recent analytical techniques to be used in biomarker characterization. The 
experimental part consisted of the third chapter of this Dissertation. It describes the 
“fieldwork”, the selection of the individual and sample collection, and the laboratory 
work where samples were treated, and the analytical method was developed in terms of 
optimization and validation and finally, in order to explore its analytical and 
discriminatory potential, the developed method was applied to real samples of asthmatic 
children and healthy controls. At the end, it can be found the fourth and last chapter of 
this Master Dissertation concerning the main conclusions and my future perspectives. 
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Chapter I – Epidemiology, etiology, 
pathophysiology and pathogenesis of asthma 
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Epidemiology, etiology, pathophysiology and pathogenesis of asthma 
 
3 
 
1.1 The epidemiology of childhood asthma – a social and economic burden 
 
1.1.1 Prevalence and incidence 
All over the world, about 334 million people of all ages and ethnicities might 
suffer of asthma. It affects not only the asthmatic population but also their families, health 
system and government [1, 2]. A study carried out by the International Study of Asthma 
and Allergies in Childhood (ISAAC), which involved a total of 306 centers in 105 
countries in all Phases and about 1.2 million children in the third Phase, concluded that 
the symptoms of asthma are more common than initially thought. Asthma is the most 
common childhood chronic airway disease in the high-income countries, more common 
in these countries than in the low- and middle-income counterparts although some of these 
also had high prevalence of asthma symptoms (current wheeze – wheeze in the past 12 
months). ISAAC concluded that the prevalence of asthma symptoms among adolescents 
(13-14 years old) varied from values above 20% in English language countries (e.g. 
32.6% in Wellington, New Zealand) and Latin America and values below 5% in countries 
belonging to the Indian Sub-Continent, Asia-Pacific (e.g. 0.8% in Tibet, China), Eastern 
Mediterranean and Northern and Eastern Europe (Figure 1A). 
 
Figure 1 – Prevalence of (A) asthma symptoms and (B) severe asthma symptoms among 13-14-year-old 
children. Symbols indicate prevalence values of < 5% (blue squares), 5 to < 10% (green circles), 10 to < 
20% (yellow diamonds) and > 20% (red stars). Adapted from [3]. 
 
Similar results were found among children (6-7 years old). It was observed a 
prevalence above 20% in almost all English language and Latin America countries (e.g. 
37.6% in Costa Rica) and the lowest prevalence (< 5%) was in the Indian Sub-Continent 
(e.g. 2.4% in Jodhpur, India), Asia-Pacific and Northern and Eastern Europe. According 
to ISAAC, low- and middle-income countries, which represents 85% of world population, 
have the highest prevalence of severe asthma including African, Indian Sub-Continent 
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and Eastern Mediterranean countries for adolescents and Africa, Latin America and East 
of the Mediterranean (Figure 1B) for children with about 50% of them with current 
wheeze [1, 3] possibly due to the lack of resources [4]. Globally, 4.9% of children had 
symptoms of severe asthma (e.g. regular exacerbations and daily asthma symptoms), 
while this number increase to 6.9% among adolescents [3]. This study also obtained an 
increase in the global prevalence of asthma between the 1990s (ISAAC Phase I) and the 
2000s (ISAAC Phase III), from 11.1% to 11.6 among children and from 13.2% to 13.7% 
among adolescents. In general, asthma is becoming more frequent and the “gap” between 
the high-income and the middle- and low-income countries is becoming less apparent [1]. 
In part, it is believed that the asthma incidence is increasing in the last decades due to 
urbanization and western lifestyle being expectable that in 2025, this increase will be 
more pronounce since urbanization will reach 45% to 59% and the asthmatic population 
will account for more than 400 million people worldwide [5]. 
Globally, 400 thousand people died from asthma in 2015. Even though this 
number is concerning, compared to 1990, it reflects a decrease of 26.7% in mortality due 
to better treatments and to the development of medicine. Asthma prevalence has increased 
about 12.6% during these 25 years being the most prevalent chronic respiratory disease 
worldwide [6]. 
 
The social burden of asthma in Portugal 
The Global Allergy and Asthma European Network (GA2LEN) defined asthma as 
“the patient ever had asthma throughout his life” and at least one of the following 
symptoms in the last 12 months: “wheeze or whistling”, “waking with chest tightness”, 
“waking with shortness of breath” and “waking with an attack of coughing” [7]. 
According to this definition, in 2012, Sa-Sousa et al. [8] estimated that about 7.8% of 
people suffered from asthma in Portugal and 10.5% suffered from asthma at some point 
in their life. The same authors improved the specificity of this definition and included the 
“asthma attack” and “waking with breathlessness” and withdrew the “waking with a 
feeling of tightness in chest” and “waking with cough”. According to this new definition 
of “current asthma”, they estimated the prevalence of asthma in Portugal at 6.8% 
comparable to European Union (EU): Gothenburg, Sweden – 7.1%; Krakow and Lodz, 
Poland – 7.1% and 6.0%; Amsterdam, Netherlands – 6.4%; Belgium – 7.6% and 
Brandenburg, Germany – 6.3% [7]. Most of the individuals (72.8%) who suffered from 
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asthma at some time in their life (10.5%) had their first exacerbation before age 18. From 
the individuals with “current asthma”, 5.7% also had chronic bronchitis and 52.3% had 
rhinitis. Among individuals under 18 years of age, the prevalence of “current asthma” 
was around 7.2% and it is only surpassed by individuals over 65 (8.0%). In older 
individuals, between 18-65 years old, the prevalence was of about 6.3%. According to 
ISAAC, the incidence of asthma symptoms (wheeze) in the last 12 months in Madeira, 
Portugal (Table 1) was of about 14.5% in 1995, decreasing significantly to 11% in 2002 
among children aged 6-7 years. Among adolescents with 13-14 years old, the values did 
not change significantly in the same period of 7 years remaining between the 9 to 10.2% 
[9]. Although in 1995, Funchal was the region of the country with the highest rate of 
asthma among 6-7 years children, it was the only region covered by the study where the 
same rate decreased significantly between 1997 and 2002, with a highest rate of asthma 
among 6-7 years old  in the Centre – Lisbon (14.1%), North – Oporto (13.1%) and South 
– Portimão (13.2%) [9]. 
 
Table 1 – Results of the surveys proposed by ISAAC on the different Regional Centers in Portugal. 
Percentages indicate the percentage of the population that suffered symptoms of asthma (wheezing) in the 
last 12 months (“current asthma”) between Phases I (1995) and III (2002) of the study. Lifetime asthma 
and wheeze refers to the populations surveyed who have had these symptoms at least once in their lifetime 
[9]. Abbreviations: N – number of individuals of the study population; % – percentage of individuals of the 
study population, asterisk refers to significant differences between the % of 1995 and 2002.  
Region Age % (N), 1995 % (N), 2002 p value 
Lisbon 6-7 12.8 (2115) 14.1 (2484) 0.177 
13-14 10.9 (3030) 14.6 (3029) <0.001* 
Funchal 6-7 14.5 (1732) 11 (1821) 0.001* 
13-14 10.2 (3313) 9.0 (3163) 0.103 
Portimão 6-7 10.7 (1189) 13.2 (1071) 0.069 
13-14 8.0 (1058) 9.7 (1109) 0.164 
Oporto 13-14 7.2 (3100) 13.1 (3337) <0.001* 
Coimbra 13-14 8.1 (926) 10.7 (1177) 0.043* 
Total 6-7 12.9 12.9 0.983 
13-14 18.2 21.8 <0.001* 
Lifetime asthma 6-7 11 9.4 0.008* 
Lifetime wheeze 6-7 28.2 28.1 0.936 
 
1.1.2 Economic impact 
Part of the injury caused by asthma is related to the economic costs, one of the 
highest among chronic diseases due to the high healthcare needed to treat this condition. 
In high-income countries, they vary from some tens of millions to thousands of millions 
US dollars [1]. Direct costs are related to treatment, prevention, and management and 
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accounted for the greatest part in most of the studies (53-100%) reviewed by Bahadori et 
al. [10]. It is estimated that 47-86% of these costs are related to hospitalization and 38-
89% are related to medication. Indirect costs accounted for 52-75% of the overall costs 
and include, for example, school days missed by the asthmatic children, work days missed 
by their parents, loss of productivity and waiting time. Asthma costs varies with the 
quality of the health system, location and level of education and are strongly related to 
symptoms, age, and severity. The asthmatic children have a much higher indirect cost 
proportion than healthy children and adult asthmatics [10]. Generally, when an asthmatic 
child is with symptoms, it is unable to continue their most common activities such as 
school. If it becomes worse, the child needs immediate medical treatment, sometimes 
requires more intensive care and hospitalization. In the US, pediatric patients are nearly 
half of asthma hospitalizations (44%) being this disease the third highest cause of 
hospitalization among children in this country [11]. Usually parents need to miss work to 
take care of their children. Thus, asthma and especially under-treated asthma, causes great 
economic health care costs (preventive and reliever medicine, devices used in treatments 
such as spacers and aerosols, ambulatory care, emergency, hospital care, patient 
education, management and planning) and productivity losses [1]. Despite this, It is 
believed that an increase in medical expenses leads to a reduce in the total health care and 
in the indirect costs due to the improvement of the control level of the asthmatic patients 
[10]. 
 
1.2 An etiologic, pathophysiologic and pathogenetic approach 
Asthma is defined by some authors as a syndrome [12]. Although this definition 
is contested by other authors [13], a clear consensus says that asthma is a heterogeneous 
disease with both genetic and environmental components. Genetic factors are defined by 
the genes related to the development of asthma [14, 15]. Atopy is a genetic predisposition 
for the development of an immunoglobulin E (IgE)-mediated response to common 
aeroallergens [16]. In addition, asthma is not equally distributed between sexes in some 
way due to hormonal factors [17]. Environmental components are related to a multitude 
of factors including aeroallergen exposure [18], viral or bacterial infections [19], active 
or passive smoking [20] as well as in utero tobacco smoke exposure [20] that associated 
to parental stress leads to the development or complication of asthma, good nutrition as a 
way to treat or prevent asthma [21], exercise that leads to the manifestation of symptoms 
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in most patients [22], climatic conditions like extreme temperatures and high humidity 
that are associated to the behavior of asthma and development of exacerbations [23]. 
Asthma is described as chronic inflammation and long-term irreversible 
remodeling of the airways. Furthermore, it is also defined by the clinical history of 
respiratory symptoms such as: dyspnea, wheeze, breathless, chest tightness, cough and 
variable expiratory airflow limitation that vary over time and in intensity [24-27]. When 
associated to one or more triggers (with an additive or synergetic effect on the 
development of mild symptoms or exacerbations [27]), this symptoms can culminate in 
an inappropriate inflammatory response: contraction of the airways and consequent 
narrowing and obstruction of the lumen due to airway wall edema and the excess of mucus 
(Figure 2). The excess of airway mucus is a common characteristic of asthma and is 
associated to an increase of mucin secretion (glycoproteins that are the main constituent 
of mucus) by hypertrophied submucosal glands related to the large cartilaginous airways, 
where its excessive secretion can be cleared by cough; and goblet cells hyperplasia related 
to the small non-cartilaginous airways, which clearance cannot be made through cough 
but rather by a healthy mucociliar system instead. The compromised small airways by 
goblet cells hyperplasia leads to mucus plugging and consequently to airway obstruction 
having a more significant effect on the pathophysiology of asthma than the hypertrophied 
submucosal glands [28]. 
 
Figure 2 – Obstruction of the airways by mucus in asthmatic patients. (A) Longitudinal section of a 
bronchus (arrow) completely obstructed by mucus (M) in a fatal case of severe asthma. (B) Cross-section 
of a bronchus that suffered bronchoconstriction. Epithelium (arrow) with folds formed by contraction of 
the smooth muscle and occlusion by mucus (M) of the remaining luminal space in a fatal case of severe 
asthma. (C) Cross section of a bronchiole showing incomplete release or “continuity” of mucin segregated 
by the goblet cells of the airway epithelium (arrows) in a case of asthma. Adapted from [29]. 
 
1.2.1 Clinical diagnosis and classification of asthma 
Currently, there are no single diagnostic methods or specific biomarkers for the 
detection of asthma, especially in children. This disease is suspected whenever the subject 
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has recurrent episodes of wheezing and cough. Usually, it is made by long-term follow-
up, extensive differential diagnosis and by the response of the subject to bronchodilator 
or anti-inflammatory treatment. 
As described by the Global Initiative for Asthma (GINA) [24], a current standard 
asthma diagnosis is typically performed based in two criteria: pattern of respiratory 
symptoms (e.g. wheezing, dyspnea, chest tightness and cough) and variable airflow. 
Asthma is often characterized by persistent symptoms or recurrent exacerbations 
triggered by numerous agents such as allergens, irritants, exercise, laughter, changes of 
weather and viral infections. It is also common for the asthmatic patients to have a 
personal history of variable respiratory symptoms and atopy (e.g. rhinitis, conjunctivitis, 
and eczema). The clinical diagnose begins with a physical examination in order to 
confirm symptoms of asthma or other atopic conditions that support its diagnosis. 
The lung function evaluation is an important step of an asthma diagnosis and 
therapeutic response. For this purpose, spirometry is often used, a technique 
recommended for patients older than 5-7 years, in which among the obtained data, it is 
highlighted the forced expiratory volume in 1 second (FEV1) and the peak expiratory flow 
(PEF). The tabulated FEV1 values for an asthma diagnosis in children is of at least 80% 
of the predicted and this value should be reversible in more than 10-12% or 200 mL after 
bronchodilation (i.e. use of a bronchodilator short- or long-acting β2-agonist) [24, 26, 30]. 
In other situations, techniques including bronchial provocation (e.g. methacholine 
or histamine challenge), exercise challenge, allergy tests (e.g. skin prick tests or 
measurement of specific IgE in serum), chest x-ray, fractional concentration of exhaled 
nitric oxide (eNO) quantification, exhaled breath condensate (EBC) analysis, eosinophil 
counting in serum or induced sputum and quantification of histamine release by basophils 
may be indicative of an allergic inflammation [24, 26]. In order to validate the 
interpretation of the results obtained by less invasive techniques, more evasive techniques 
including tissue analysis such as endobronchial biopsy or bronchoalveolar lavage (BAL) 
are used. These techniques cannot be used routinely in children once they require strong 
sedation [31]. 
In an initial clinical approach, asthma is classified according to its severity based 
on symptoms, frequency, air flow limitation and lung function variation. Thus, asthma is 
classified as persistent or intermittent. Persistent asthma can also be sub-classified as 
mild, moderate or severe (Table 2). Based on this classification, the most appropriate 
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treatment for the patient can be determined. The classification of asthma in a given patient 
may change over a period of months or years. Thus, in a first approach, asthma can be 
classified as severe persistent and then, at a later stage, be classified as moderate persistent 
if there is a good response to treatment [32]. In further assessments, asthma is dynamically 
classified based on its level of control: well controlled, partly controlled and uncontrolled 
with high relevance in clinal practice towards which asthma management is evaluated 
[30]. 
 
Table 2 – Classification of asthma by gravity based on clinical characteristics prior to treatment [32]. 
Classification Clinical symptoms 
Intermittent Presents symptoms less than once a week; 
Short term exacerbations; 
Nocturnal symptoms no more than 2 times a month 
− Prediction of FEV1 or PEF ≥ 80% 
− Variability of PEF or FEV1 < 20% 
  
Mild persistent Present symptoms more than 1 time per week but less than 1 time 
per day 
Exacerbations can affect activity and sleep 
Nocturnal symptoms more than 2 times per month 
− Prediction of FEV1 or PEF ≥ 80% 
− Variability of PEF or FEV1 < 20-30% 
  
Moderate persistent Present daily symptoms 
Exacerbations can affect activity and sleep 
Nocturnal symptoms more than 1 time per week 
Daily use of short-acting β2-agonists 
− Prediction of FEV1 or PEF = 60-80% 
− Variability of PEF or FEV1 > 30% 
  
Severe persistent Present daily symptoms 
Regular exacerbations 
Regular nocturnal symptoms 
Limitation of physical activity 
− Prediction of FEV1 or PEF ≤ 60% 
− Variability of PEF or FEV1 > 30% 
 
1.2.2 Atopic asthma – from a phenotype to an endotype classification 
In 1947, Francis Rackemann classified asthma in two clinically distinct main 
phenotypes: atopic or extrinsic asthma and non-atopic or intrinsic asthma [33]. The atopic 
phenotype is highly related to allergies, characterized by airway hyperresponsiveness, 
infiltration of the mucosa with eosinophils and type 2 T helper lymphocytes (Th2), 
circulating specific IgE and positive skin prick tests to common allergens (e.g. pollens, 
mold, mites and animal epithelia). It is more common, contributing with about 73% of 
the asthmatic cases and arises earlier, before 30 years old. Its diagnosis is relatively simple 
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and generally based on clinical and familiar history. It may complicate due to infections 
and it is also associated to asthmatic bronchitis, cough and rhinitis that can lead to a severe 
form of asthma. Non-atopic asthma is hard to diagnose once its patients do not have a 
clinical familiar history of allergies, having its origin in factors that are not related to 
allergies such as bacterial infections. “Polypoid sinusitis”, dyspnea, negative skin prick 
tests and total IgE concentration in serum between the normal values without significant 
evidence of specificity to common aeroallergen, are common characteristics among these 
individuals. They show sensitization to aspirin more frequently, and psychosomatic 
exhaustion factors are also considered. This phenotype affects about one fourth (i.e. 27%) 
of the asthmatic population that tend to be older than the atopic asthmatics (older than 30-
40 years old) with a predominance of female individuals [18, 33-35]. 
According to Bacharier et al. [26], phenotypes of asthma are defined by age and 
triggers. Symptoms persistence (i.e. wheezing) in infant children (0-2 years old) is an 
important indicator of severity. Among preschool children (3-5 years old), symptoms 
persistence during the last 12 months is a differentiating indicator of asthma phenotype. 
Depending on the symptoms, asthma can be classified as virus- (more common at this 
age), exercise- or allergen-induced. Among school-age children (6-12 years old), even 
though symptoms are comparable to those of preschool children, the allergen-induced 
asthma becomes more common and apparent. Seasonality may become evident and 
severity can become an issue due to the lack of response to therapy and lung function. In 
adolescence (13-16 years old), atopic asthma has more new cases than remissions and 
non-atopic asthma can have its onset. Some issues like smoking, follow-up of therapy, 
and change of the pediatric to another physician have their beginning at this age. A study 
by de Blic et al. [36] suggested that severe asthma could also be considered as a unique 
standalone phenotype. It is age-dependent, related to persistence and to a poor response 
to therapy and can be measured by the frequency of symptoms and lung function. In infant 
children, persistence should be considered as severe asthma, in older children, severe 
exacerbations are those with respiratory distress with need of oxygen and consequent 
hospitalization [26]. 
Despite the classification of asthma in different phenotypes being extensively 
used, it has shown to be insufficient regarding its heterogeneity at a molecular level and 
its failure in correlating inflammation, damage functional impairment and symptoms [37]. 
In order to make progress in terms of new treatments, preventions and cures, a recent 
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approach has sub-classified each phenotype into groups based on their different 
pathogenetic mechanisms at a molecular and cellular level, and based on their response 
to treatment – endotypes [37, 38]. The allergic asthma phenotype is defined by different 
endotypes including Th2-driven inflammation (allergen exposure), eosinophilic 
inflammation (eosinophils infiltration in the mucosa), responsive to steroids, responsive 
to allergen immunotherapy, responsive to anti IgE and responsive to specific cytokines 
such as interleukin (IL)-4, IL-13 and IL-5 [39]. The sub-classification of the phenotypes 
into endotypes gives the opportunity to identify biomarkers of disease and consequently 
guide to a better and more precise diagnosis that leads to a personalized treatment and 
management [38]. 
 
1.2.3 Pathogenesis of inflammation in allergic asthma 
Airway inflammation is an inherent feature of allergic asthma. A better 
understanding of the specific steps of this process, may improve the advance of new 
therapies which can be applied to patients and consequently improve the control of asthma 
and its symptoms. 
The genetic predisposition to trigger a local IgE-mediated response (i.e. atopy) 
and the environmental influence, such as timing and allergen dose to which the subject is 
exposed, contribute to the appearance of an inappropriate inflammatory response to 
allergens that, in a normal situation, should be harmless [27, 40]. 
Allergic inflammation in asthma comprises a well-orchestrated interaction 
between the immune system and the respiratory epithelium. An ideal immune function 
depends on the dynamic balance between both innate and adaptive systems and their 
immunoregulatory components [40]. The innate immune system forms a peripherical 
network of immunological surveillance in order to initiate an immediate beneficial 
response against foreign agents [41]. The adaptive immune system generates 
lymphocytes that circulate between the lymphatic and the blood circulatory systems 
capable of mounting an antigen-specific immune response able to acquire long lasting 
memory against the same antigen [42]. Even though the definition of both systems seems 
clear, their distinction has become increasingly difficult because of their dynamic 
interaction [40]. 
Allergic asthma is widely dependent on IgE sensitization. Airway inflammation 
is a response of the immune system to injury which, in a normal situation, should be 
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advantageous. In an anomalous situation, such an allergic asthmatic reaction, the 
inflammatory response leads to a chronic inflammation in the presence of non-pathogenic 
agents. In these cases, exacerbations can occur even in the absence of continuous allergen 
exposure. The combined action between the multi-cellular inflammatory infiltrate and the 
parenchymal lung tissue cells is performed by bioactive mediators such as eicosanoids, 
antibodies, cytokines and growth factors [40]. 
The inflammatory cascade associated to asthma, is a process that consists of 4 
main phases: (i) sensitization or antigen presentation phase, (ii) re-exposure to the 
allergen, (iii) airway remodeling, and (iv) resolution. In this chapter, it is briefly described 
the main phases of the inflammatory process. 
 
 Sensitization 
The development of allergic asthma involves sensitization to a specific allergen 
which can arise years before the onset of the characteristic symptoms of asthma (Figure 
3). This phase occurs when the allergen (i.e. antigen) stimulates the production of Th2. 
These Th2, do not react directly to allergens. They have antigen-presenting cells (APCs) 
as intermediates, such as dendritic cells (DCs), considered the most powerful APCs, that 
constantly scan the airways through pattern recognition receptors associated to damage 
or pathogenic agents, promoting their detection and elimination. The activation of Th2 
from naïve CD4+T cells by APCs leads to the synthesis of inflammatory cytokines (e.g. 
IL-4 and IL-13) that stimulate the interaction between Th2 and B-lymphocytes to 
proliferate and synthesize specific IgEs for the antigen. The specific IgEs circulate in the 
blood stream and bind essentially to high affinity IgE receptors (FcεRI) – more common, 
present on mast cells surface of the airways epithelium and lower layers of the mucosa, 
and on the peripheral blood basophils, less abundant granulocytes, which are found in the 
blood making them highly reactive – or to low affinity IgE receptors (FcεRII) – present 
on a wide variety of leukocytes, making these cells accessible to the allergen in a future 
re-exposure [40, 43-45]. 
The genetic predisposition for atopy, and the continuous exposure to factors with 
a harmful effect to a good lung growth and proper development of the immune system, 
immature at an early age, such as alcohol, active or passive smoking (particularly during 
pregnancy), air pollution and exposure to volatile chemicals influence the sensitization 
process. The constant exposure to antigens and the systematic stimulation of asthma 
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symptoms, intensify their persistence throughout life as well as decrease the probability 
of remission [43, 46]. 
 
 Re-exposure to the allergen 
A re-exposure to the allergen, leads to a complexity of intercellular signaling 
events that promote the degranulation and discharging of mediators (e.g. proteases), 
cytokine transcription, histamine and synthesis of eicosanoids derived from 
phospholipids such as serotonin, leukotrienes (LTs) and prostaglandins (PGs) by mast 
cells and basophils. These mediators cause the early-phase (i.e. acute-, immediate-phase) 
reaction (Figure 3) characterized by airway hyperresponsiveness, mucus hypersecretion 
and vasodilation (bronchospasms and edema) before inflammatory cells recruitment. At 
this time, occurs activation of macrophages and production of reactive oxygen species 
(ROS) [40, 44, 45] as will be discussed in more detail later. 
After hours or days, about half of the asthmatic patients experience the late-phase 
(i.e. chronic phase) reaction (Figure 3) characterized by the strong infiltration of Th2 in 
the mucosa, mediated by eosinophilic inflammation [47] and the involvement of 
macrophages, epithelial, endothelial and smooth muscle cells that promote the chronic 
inflammatory symptoms of asthma by producing their mediators such as chemokines, 
cytokines and LTs [44, 45]. 
Mast cells are an initial source of IL-4 and IL-5 (recruitment, differentiation, 
proliferation and maturation of eosinophils present in the vascular system). Absent in 
non-asthmatic patients such as eosinophilic bronchitis patients, they are recruited and 
maintained by the smooth muscle of the airways of asthmatic individuals responsible for 
the characteristic airway constriction [40]. Eosinophils are found mainly in the lung tissue 
and BAL of asthmatic patients. Their precursors, CD34+ cells, are recruited from the bone 
marrow to the lungs by the release of PGs, cysteinyl-LTs (cys-LTs), cytokines and 
chemokines. Its selective recruitment to the airways is driven by chemoattractant eotaxins 
synthesized by the epithelial cells in response to IL-5 and IL-13 from Th2 and degranulate 
to release cationic proteins, harmful to the lung tissue. Some studies also demonstrated 
that eosinophils have the ability to activate the pathogenic response of Th2 [48]. Chronic 
inflammation becomes persistent due to the repetitive cycle of tissue damage and 
inflammatory cells recruitment, even in the absence of allergens [40, 45, 49]. Basophils 
act in the same way as eosinophils. They have FcεRI, APC function and release 
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eicosanoids and histamine by degranulation contributing to the pathogenesis of asthma 
[40]. 
 
Figure 3 – Sensitization, early-phase and late-phase reaction in the inflammatory response. Abbreviations: 
APC – antigen presenting cell; IL – interleukin; IgE – immunoglobulin E; FcεRI – high affinity IgE 
receptor. Adapted from [47]. 
 
Even though eosinophilic inflammation is the most common type of asthma and 
even considered a distinct endotype, neutrophils have also been associated with cases of 
severe asthma, exacerbations and non-atopic asthma, being considered a distinct endotype 
represented in a significant group of asthmatics, who respond poorly to corticosteroids 
[40]. 
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The Th2, cell biomarkers of disease severity, migrate into the lungs and allow the 
airways to recognize and respond to the presence of allergens. Their effect is amplified 
by the production of inflammatory cytokines such as IL-4, -5, -9, -13 and -25 promoting 
the IgE production, inflammation, airway hyperresponsiveness and remodeling [40]. 
The presence of lymphocytes with characteristics from both innate and adaptive 
immune systems are classified as non-classical lymphocytes. These cells include natural 
killer cells (NKs), NK T cells (NKTs) and γδT cells. NKs are naturally present in the 
lungs. However, although their role is still questionable, they were observed in an 
increased concentration in asthmatic patients. The activation of NKTs by glycolipids 
promotes the synthesis of Th1 and Th2 cytokines (e.g. IFN-γ and IL-4). In the same way 
as NKs, γδT cells were found in a greater concentration in asthmatic patients essentially 
during periods of exacerbations being considered as both regulators of airway 
homeostasis or pro-inflammatory mediators [40, 49]. 
 
 Airway remodeling 
The characteristic chronic inflammation of the asthmatic patients is typically 
accompanied by changes in tissues at the level of extra cellular matrix, protein deposition, 
basement membrane, increased smooth muscle mass, nerves, vessels and epithelial 
barrier function followed by hyperplasia –  airway remodeling. These changes contribute 
to the thickening of the airway walls and to the decrease of the airway diameter resulting 
in obstruction, hyperresponsiveness and poor patient response to therapies such as 
corticosteroids, β2-agonists and anti-LTs [40, 43]. 
The transforming growth factor (TGF)-β is upregulated in the asthmatic airways 
and is considered the main regulator of remodeling. It promotes the synthesis of 
extracellular matrix and the transformation of myofibroblasts from airway smooth muscle 
and fibroblasts, which in a normal individual would have a repair function. However, in 
asthmatic patients, myofibroblasts appear to be correlated with thickening of the 
basement membrane. In addition, TGF-β propagates the airway remodeling through the 
induction of pro-inflammatory mediators with effect on smooth muscle contractibility. 
Other mediators identified in asthmatic airways contribute to remodeling, such as platelet-
derived growth factor that promotes proliferation of fibroblasts and smooth muscle; and 
the vascular endothelial growth factor that promotes angiogenesis and irregular 
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production of extracellular matrix metalloproteinases responsible for matrix degradation 
during remodeling [40, 44, 45]. 
 
 Resolution 
The resolution phase of the inflammatory process in asthma concerns 
homeostasis. It includes the removal of apoptotic cells and release of IL-10 with anti-
inflammatory function by restoring tissues and growth factors that lead to the return of 
tissue integrity [40, 44, 50]. 
The chemokine receptor D6 as well as certain infiltrating leukocytes have a 
resolution function by cleansing inflammatory chemokines that recruit leukocytes. 
During this step, other anti-inflammatory agents are also produced among which lipid 
mediators, such as resolvins and protectins, produced from eicosapentaenoic acid and 
docosahexaenoic acid in order to control the infiltration of granulocytes. In this way, they 
prevent the release of pro-inflammatory chemokines and activation of inflammatory cells, 
promoting the clearance of inflammatory cells [40]. 
 
1.3 The role of enzymatic and non-enzymatic lipid peroxidation in asthma 
During lipid peroxidation, a polar group hydroperoxide (-OOH) is added to the 
hydrophobic tails of the unsaturated fatty acids. Hydroperoxide lipids are generally 
characterized as harmful since they lead to changes in lipid-lipid and lipid-protein 
interactions, to the formation of free radicals and to interruptions in the functions of cell 
membranes, compromising the integrity of organelles and cell as a whole. However, if 
lipid peroxidation occurs in a controlled manner in specific cell sites, it may have 
beneficial effects on the organism such as destructive processes of cell metabolism, cell 
differentiation and cell maturation, which require changes in cell and subcellular 
membranes. Hence, it is expected that lipid peroxidation can be activated or deactivated 
when necessary and its level of control is not possible by non-enzymatic reactions thus, 
different enzymes are involved in this process [51] such as the lipoxygenases (LOs) 
inherent to the LTs and lipoxins (LXs) pathway [51, 52] and the cyclooxigenases (COXs) 
inherent to the pathway of PGs and thromboxane A2 (TXA2) [53]. 
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1.3.1 The arachidonic acid cascade – an enzymatic peroxidation approach 
As discussed before, mast cells play an important role in the inflammatory 
response by the release of pro-inflammatory mediators such as LTs and PGs with origin 
on the arachidonic acid present in the cell membrane. 
The arachidonic acid cascade (Figure 4) begins with its hydrolysis under the action 
of phospholipase A2. Its enzymatic oxidation is mediated by COXs, LOs and 
epoxygenases (EPOXs) leading to the formation of important bioactive metabolites 
belonging to the group of eicosanoids – oxygenated polyunsaturated fatty acids (PUFAs) 
containing 18 to 22 carbons [54]. Even though metabolites derived from the EPOX 
pathway, epoxyeicosatrienoic acids, are of great importance to the body as blood pressure 
regulators in addition to their beneficial effects on the vascular, cardiac, nervous and renal 
system [55], it will be essentially discussed over this master dissertation, metabolites 
derived from the COXs and LOs pathways such as (i) LTs (eicosanoids containing 3 
conjugated double bonds, trienes), (ii) PGs (eicosanoids containing a 5 carbon ring) and 
(iii) LXs (distinguished by having a system of 4 conjugated double bonds, tetraenes) since 
they are powerful inflammatory mediators and are directly related to atrophy and 
weakening of airway muscles in chronic respiratory diseases  [52, 56-58]. 
 
Figure 4 – The arachidonic acid cascade. An enzymatic pathway that leads to the formation of bioactive 
eicosanoids. Abbreviations: 5-HPETE, arachidonic acid 5‑hydroperoxide; LXY, lipoxin XY, LTXY, 
leukotriene XY, PGXY, prostaglandin XY, TXY, thromboxane XY. 
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In Table 3 is shown studies perform with different analytical strategies to 
characterize the eicosanoids levels present in different biosamples of asthma and COPD 
sufferers. 
 
 Leukotrienes 
After hydrolysis, the arachidonic acid is converted by the enzyme 5-LO and the 
5-LO-activating protein (FLAP) into 5-hydroperoxyeicosatetraenoic acid (5-HPETE) by 
the insertion of a hydroperoxide group (-OOH) into the carbon 5 of the arachidonic acid. 
A subsequent dehydration reaction, catalyzed by the 5-LO, results in the formation of 
LTA4 [54, 59]. This LT is a precursor of the LTB4, a dihydroxy leukotriene, when 
hydrolyzed by the action of the enzyme LTA4 hydrolase. The LTA4 can be also converted 
to cys-LTs (LTC4, LTD4 and LTE4), when conjugated to intracellular reduced glutathione 
(GSH) by the enzymatic action of LTC4 synthase [52, 57]. The FcεRI-mediated release 
of LTC4 by mast cells, depends essentially on the levels of intracellular GSH. The 
intracellular GSH levels increase with the levels of oxidative stress leading to the 
intensification of inflammation [54, 59, 60]. LTs formation is controlled by the 
differential expression of enzymes in cells. For example, neutrophils express LTA4 
hydrolase and produce LTB4 whereas mast cells and eosinophils express LTC4 syntax 
and produce LTC4 although transcellular biosynthesis occurs in 60 to 70% of cases. This 
process occurs, for instance, when a cell A (e.g. neutrophil or mast cell) produces LTA4 
which is then used by a cell B to produce LTC4 (e.g. platelets) or LTB4 (e.g. erythrocytes) 
[54]. 
The LTB4 (Figure 5) is a powerful proinflammatory chemoattractant whose main 
target are neutrophils promoting their activation, adhesion to endothelium and chemotaxis 
– selective recruitment to the lungs. The signaling of these eicosanoids is mediated by 
both LTB4 receptor-1 of high affinity and specificity, and LTB4 receptor-2 of low affinity 
and specificity. These receptors also differ in their distribution in tissues and belong to 
the family of G protein-coupled receptors. The LTB4 also activates degranulation and 
release of other mediators such as IgEs and cytokines, enzymes and superoxides in 
neutrophils, and it is also involved in inflammatory pain by processes dependent on these 
neutrophils. It also has a ligand function for the peroxisome proliferator-activated 
receptor alpha (PPAR-α), which plays a key role in the oxidative degradation of fatty 
acids and their derivatives including LTB4 itself [52, 59].
  
Table 3 – Relevant studies that investigated levels of eicosanoids behavior among asthmatic populations, COPD sufferers and healthy individuals. Abbreviations: LXY – lipoxin 
XY; LTXY – leukotriene XY; PGXY – prostaglandin XY; TXY – thromboxane XY; EBC – exhaled breath condensate; COPD – chronic obstructive pulmonary disease; AIA – aspirin-
induced asthma; ATA – aspirin-tolerant asthma; MEPS – microextraction by packed sorbent; LL – liquid-liquid extraction; EIA – enzyme immunoassay; SPE – solid-phase 
extraction; UHPLC – ultra-high performance liquids chromatography; UHPLC-PDA – UHPLC-photodiode array; UHPLC-MS/MS – UHPLC-tandem mass spectrometry; GC 
– gas chromatography; GC-NICI-MS – GC-negative ion chemical ionization-mass spectroscopy; GC-MS – GC-mass spectrometry; ANOVA – analysis of variance. 
Analyte Biosample Population Groups Extraction 
platform 
Analytical 
platform 
LOD/LOQ Statistical analysis Comments Ref. 
LTB4 Urine Adults and 
children 
Case vs 
control 
MEPS UHPLC-
PDA 
0.37/1.22 ng/mL 
 
Increased in asthmatics [61] 
LTB4 Sputum - (COPD) Case vs 
control 
LL UHPLC-
MS/MS 
-/0.2 ng/mL 
 
Increased in COPD 
patients 
[62] 
LTB4 EBC Children Case vs 
control 
EIA - 4/- pg/mL Spearman's correlation, 
Mann-Whitney and 
Wilcoxon signed-rank 
test 
Increased in asthmatics [63] 
Cys-LTs and 
LTB4 
Sputum - Case vs 
control 
SPE UHPLC-
MS/MS 
9.8/19.5 pg/mL 
 
Increased in 
asthmatics. 
Undetectable LTC4 
[78] 
11βPGF2α and 
LTE4 
Urine and 
plasma 
Adults AIA vs 
ATA vs 
control 
SPE GC-NICI-
MS 
- Pearson's correlation 
and ANOVA 
Increased in asthmatics [65] 
11βPGF2α Urine Adults AIA vs 
atopic vs 
control 
EIA - 15.6/- pg/mL T test Increased in atopic 
asthmatics and AIA 
after induction 
[79] 
11βPGF2α and 
LTE4 
Urine Children Case vs 
control 
and 
obese vs 
non-
obese 
EIA - - Wilcoxon signed-rank 
and Kruskal-Wallis test 
Increased only in 
asthmatics. More 
pronounced in obese 
asthmatics 
[80] 
Cys-LTs, TXB2, 
PGE2, PGD2 
and PGF2α 
Sputum Adults Case vs 
control 
EIA (Cys-LTs) 
and LL (PGs 
and TX) 
GC-NICI-
MS 
 
Pearson's correlation 
and Kruskal-Wallis test 
Increased Cys-LTs in 
asthmatics. More 
pronounced in 
persistent and severe 
asthma.  
[81] 
Cys-LTs and 
LTB4 
EBC Adults and 
children 
Case vs 
control 
LL GC-MS 1/- pg/mL Spearman's correlation, 
Kruskal-Wallis and 
Mann-Whitney test 
Increased in asthmatics [82] 
LTB4 and LXA4 EBC Children Case vs 
control 
SPE and EIA 
 
3.9/- pg/mL χ2, T test, ANOVA, 
ROC and AUC 
Increased in asthmatics [83] 
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As shown in Table 3, the LTB4 levels tend to be higher in different biological 
matrices such as urine, EBC and sputum of individuals with asthma [61-63]. 
 
Figure 5 – Chemical structure of leukotriene B4. 
 
The Cys-LTs contain a cysteine amino acid in their structure and are considered 
the most powerful bronchoconstriction mediators known to date, about 100 to 1000 times 
more powerful than histamine, and play an important role in inflammatory disorders, 
particularly in asthma. They are eosinophil chemoattractants, possess a potent 
vasoconstricting and vasodilating capacity and increase vascular permeability allowing 
the migration of macromolecules from the plasma to airway edema, characteristic of 
asthma. In addition, they stimulate mucus secretion and inhibit mucociliar clearance. As 
for LTB4, the effects of these LTs are mediated by G protein-coupled receptors (Cys-LT 
receptor-1 and -2) with differential tissue distribution [52, 59]. Cys-LTs are potential 
biomarkers of asthma [64, 65] and are released following allergen exposure, exercise or 
ingestion of COX-1 enzyme inhibitors known as nonsteroidal anti-inflammatory drugs 
(NSAIDs) such as aspirin [66, 67]. The use of cys-LT receptor antagonists (LTRAs) such 
as montelukast, zafirlukast and pranlukast, as well as inhibitors of its synthesis such as 
zileuton, have been used to ease clinical symptoms of asthma [68] as well as in several 
studies in order to determine their role in the pathophysiology of this disease [67, 69]. 
Since LTC4 and LTD4 are biologically converted to LTE4 (Figure 6), little or none of 
these precursors is detected in urine. Therefore, LTE4 is considered a urinary biomarker 
of total cys-LTs [70-72] as well as a potential biomarker of asthma severity [73] (Table 
3). It has been demonstrated an increase in urinary LTE4 levels following inhalation of 
either LTC4 and LTE4 [74]. Furthermore, baseline LTE4 values are essentially related to 
age [75] and genetic predisposition [76]. 
 
Figure 6 – Chemical structure of leukotriene E4. 
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 Prostaglandins 
PGs are formed by metabolization of the arachidonic acid catalyzed by COX-1 
and COX-2 in PGH2, an unstable PG, rapidly converted by PG terminal synthases into 
bioactive PGs - PGE2, PGI2, PGF2α, PGD2 and thromboxane A2 (TXA2). PGE2 and PGD2 
can be recruited by inflammatory cells such as neutrophils, macrophages and mast cells 
[57, 58]. During an inflammatory response, the level and profile of PG production 
changes from very low values in non-inflamed tissues to very high values due to 
differential expression of enzymes in inflamed tissues [77].PGD2 is a major eicosanoid 
released by the activation of mast cells and basophils [84, 85] and plays an important role 
in both inflammation and homeostasis of the organism. For example, in the brain, it is 
involved in the regulation of sleep and other activities of the central nervous system as 
the perception of pain. It has long been associated to inflammation and atopy despite, in 
some cases, exerting anti-inflammatory functions. PGD2 can subsequently be 
metabolized into 11βPGF2α and PGs of the J series (e.g. PGJ2). It has been detected in the 
BAL fluid of asthmatic patients, concentrations about 150 times higher after an allergic 
reaction. In tests performed with this PG, it has been observed bronchoconstriction and 
eosinophilic infiltration. Its pro-inflammatory effects are mediated by DP1 and 
DP2/CRTH2 receptors. DP1 receptors are expressed in the bronchial epithelium and are 
mediators of chemokines and cytokines production that recruit lymphocytes and 
eosinophils which in turn lead to inflammation and airway hyperreactivity. In addition, 
the activation of DP1 receptors also leads to the reduction of eosinophils in allergic 
inflammation. DP2/CRTH2 receptors contribute to the pathogenic response by 
controlling cell migration (i.e. chemotaxis). PGD2 recruits Th2 and eosinophils directly 
through the DP2/CRTH2 receptors present in inflammatory cells such as Th2, eosinophils 
and basophils. The anti-inflammatory action of PGD2 is associated with the presence of 
DP1 receptors in DCs which prevents them from migrating from the lungs to the lymph 
nodes and may play a role in the immune adaptive response to antigens by reducing the 
proliferation of cytokines by antigen-specific T cells [77]. The PGD2 is not excreted in 
the urine. The first and most abundant metabolite of PGD2 is 11βPGF2α (Figure 7), which 
also has biological activity such as bronchoconstriction and contraction of the coronary 
arteries and it is enzymatically synthesized by the action of the reduced nicotinamide 
adenine dinucleotide phosphate (NADPH)-dependent 11-ketoreductase [79, 85]. 
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Figure 7 – Chemical structure of 11β-prostaglandin F2α. 
 
 Lipoxins 
Although LXs, such as LXA4 and LXB4, do not belong to the LT family, they are 
eicosanoids whose origin is mediated by LOs being the product of the action of the 5-LO 
enzyme together with 15-LO and/or 12-LO. Their main functions are cell regulation, 
inflammatory inhibition in the lungs, increase phagocytosis of macrophages, resolution 
of pulmonary edema, inhibition of cell proliferation, COX-2 activity and angiogenesis 
[52, 57]. Therefore, their expression is decreased in the airways and systemic circulation 
of patients with severe asthma [86]. 
 
1.3.2 Oxidative stress and inflammation 
Oxidative damage is defined by the injury that occurs in the body when reactive 
species outgrow the antioxidant defenses of the body [87]. 
ROS and reactive nitrogen species (RNS), either endogenous or exogenous, play 
an important role in airway inflammation and are a determining factor in the severity of 
asthma. An excess of reactive species in the organism leads to deep structural cell damage 
through oxidation of the main biomolecules including lipids, proteins and DNA [88]. 
According to the hierarchical model of oxidative stress (Figure 8) [89], when the 
organism is exposed to low levels of oxidative stress, it is able to recover cellular 
homeostasis through the production of different enzymatic antioxidants such as catalase 
(CAT), superoxide dismutase (SOD) 3, hemoxygenase-1, glutathione-S-transferase 
(GST),  quinone oxidoreductase, glutathione peroxidase (GPx) and UDP 
glucuronosyltransferase induced through the nuclear erythroid 2 p45-related factor 2 
(Nrf-2) pathway responsible for activating the transcription of more than 200 genes. Due 
to its ability to respond to low levels of oxidative stress, Nrf-2 may be a determinant 
predisposition factor to develop asthma as a response to environmental stimuli such as air 
pollution [90]. When exposed to intermediate levels of oxidative stress, which 
overwhelmed the antioxidant capacity of the organism, other potentially pro-
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inflammatory pathways are developed such as mitogen-activated protein kinase (MAPK) 
and nuclear factor (NF)-κB pathways – leading to the expression of cytokines, 
chemokines, and adhesion molecules relevant to airway inflammation and consequently 
to asthma per se. An increase to high levels of oxidative stress can lead to a mitochondrial 
cytotoxic response resulting in cellular apoptosis or necrosis [89, 91]. 
Asthma is also characterized by the unbalance between oxidant and antioxidant 
agents. Antioxidants protect cells and tissues from the continuous production of ROS and 
RNS from normal organism metabolism [92]. An unbalance in the state of redox 
homeostasis of the airways is a determining factor in the initiation of asthma and its 
severity [91]. Consequently, asthma is characterized by a loss of antioxidant activity, as 
demonstrated by Sackesen et al. [93] where they found that the SOD and GPx as well as 
non-enzymatic compounds such as glutathione, ascorbic acid, α-tocopherol, lycopene and 
β-carotene were found to be significantly lower in asthmatic children. The loss of 
enzymatic antioxidant activity (e.g. SOD, CAT and GPx) reflects the oxidative stress in 
the airways of asthmatic patients [94]. The genetic component is also reflected in the 
expression of antioxidant enzymes such as GSTs expressed in the lungs. Different 
polymorphisms with high frequency in the population lead to a loss in the expression of 
these enzymes, resulting in a pathophysiological alteration that is reflected in 
inflammation of the airways and symptoms, increase of IgE values and a histamine 
response [91]. 
 
Figure 8 – The hierarchical model of oxidative stress. At a low level of oxidative stress, several antioxidant 
enzymes are induced via Nrf-2 in order to recover the redox homeostasis. At an intermediate level, there is 
induction of proinflammatory responses by the activation of MAPK and NFκB. At a high level, apoptosis 
or cell necrosis occurs. Abbreviations: CAT – catalase; SOD – superoxide dismutase; HO-1 – 
hemoxygenase-1; MAPK – mitogen-activated protein kinase; NFκB – nuclear factor-κB; TNF – tumor 
necrosis factor; FH – fumarate hydratase; FADD – Fas-associated death domain protein; VDAC-1 – 
voltage-dependent anion-selective channel-1 protein. Adapted from [89]. 
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1.3.2.1 The role of endogenous and exogenous reactive species in asthma 
Inflammatory cells including mast cells, eosinophils, macrophages and 
neutrophils, and the epithelial and smooth muscle cells of the airway produce endogenous 
ROS (Figure 9) after their activation by a variety of stimuli [44, 91, 95]. 
 
Figure 9 – The role of endogenous and exogenous reactive species in airway inflammation. Oxidative stress 
is caused by the excess of both endogenous (produced by inflammatory cells and airway tissue cells) and 
exogenous reactive species (e.g. environmental and occupational pollution) that lead to airway 
inflammation. RNS, reactive nitrogen species; ROS, reactive oxygen species. 
 
The superoxide anion (O2•–) is produced by the nicotinamide adenine dinucleotide 
phosphate (NADP) oxidase-dependent complex, by the cytosolic xanthine oxidase system 
and by the mitochondrial electron transport chain. This species is then enzymatically or 
spontaneously (reacting with itself) converted to hydrogen peroxide (H2O2). Reactions 
with O2•– and H2O2 can be catalyzed into hydroxyl radical (OH•), a much more reactive 
species than O2•– and H2O2, by transition ions such as the iron present in the body. In fact, 
much of the damage caused by O2•– and H2O2 is due to the formation of OH•. For example, 
Fe3+ is reduced to Fe2+ (Haber-Weiss reaction; Reaction 1) and Fe2+ is then oxidized into 
Fe3+ leading to the formation of OH• and OH– from H2O2 (Fenton reaction; Reaction 2) 
[96]. OH• is also synthesized through the formation of hypohalides (e.g. hypochlorous 
acid – HOCl and hypobromous acid – HOBr) from the reaction between H2O2 and halides 
(compounds that result from the reaction between a halogen and another species) 
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catalyzed by peroxidases present in inflammatory cells such as eosinophils, neutrophils 
and monocytes. Subsequently, the hypohalides react with O2•– forming OH• [94, 97, 98]. 
The main RNS produced in the organism is NO• produced by NO synthases 
(NOS). These enzymes catalyze the conversion of L-arginine into L-citrulline with the 
generation of NO• [99]. In a normal situation, NO• is constitutively produced in small 
amounts by isoenzymes NOS1 (neuronal) and NOS3 (endothelial), which are assumed to 
play a regulatory role in neurotransmission and bloodstream respectively, or in large 
amounts when induced by cytokines or bacterial products on inflammation or infection 
by the isoenzyme NOS2 (inducible) [100, 101]. There is evidence that asthmatic patients 
show increased levels of NO• in the exhaled breath essentially due to an NOS2 
overexpression in the endothelial cells of the lungs and respiratory tract [102], although 
NOS1 and NOS3 seem to be involved [103, 104]. Even though the increased expression 
of NOS2 can be reduced by corticosteroids [105], no NO• removal system is currently 
known [106]. 
 
  O2•– + Fe3+ → Fe2+ + O2 Reaction 1 
 
 H2O2 + Fe2+ → Fe3+ + OH– + OH• Reaction 2 
   
O2•– can also react with NO• forming peroxynitrite (ONOO-), which reacts with 
proteins such as tyrosine, through its high nitration power [101, 107]. In atopic asthmatics, 
high levels of nitrotyrosine, a product of tyrosine nitration, were detected [108]. It has 
also been detected an increased concentration of peroxynitrite in the EBC of chronic 
obstructive pulmonary disease (COPD) patients [109], which in turn reduce de detectable 
values of NO• in the airways [100]. 
The reaction between radical species and lipids can culminate in the formation of 
isoprostanes, saturated hydrocarbons (e.g. ethane and pentane) and aldehydes (e.g. 
malondialdehyde) [88, 110]. Higher values of isoprostanes (i.e. 8-isoprostane, 8-isoP) 
were detected in either the exhaled breath [73, 111], urine [65] or plasma [87] of asthmatic 
patients being an in vivo way of accessing oxidative stress-related diseases such as 
asthma, diabetes and cardiovascular diseases [56]. Other products, including 3-
bromotyrosine, 3-chlorotyrosine and malondialdehyde, a marker of lipid peroxidation of 
radical action, are also indicators of the severity of asthma [112]. In 2006, Ercan et al. 
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[113] obtained increased levels of malondialdehyde and lower levels of glutathione in a 
study performed with asthmatic patients. In the same way, it was detected more than a 
10-fold increase in 3-bromotyrosine levels and a 2 to 3-fold increase in 3-chlorotyrosine 
in the BAL of asthmatic patients compared to heathy subjects after allergen challenge. 
The exposure to ultrafine particles (< 100 nm) present in air pollutants can directly 
reach the mitochondria, damaging them and making it difficult for the lungs to deal with 
the oxidative stress [114]. In addition to air pollutants, cigarette smoke and its more than 
4000 compounds distributed throughout the gaseous, tar and aqueous phase contribute 
widely to the oxidative stress. High concentrations of O2•– and NO• are present in the 
gaseous phase of smoke. The tar phase has organic radical species that react with the 
molecular oxygen (O2) present in the air and forms O2•–, H2O2 and OH–, besides being a 
powerful chelating agent of iron and generating H2O2 continuously. The aqueous phase 
of cigarette smoke also contributes since its compounds may undergo redox reactions in 
the lung epithelium [91, 94, 115]. 
 
1.3.2.2 Non-enzymatic lipid peroxidation in asthma 
One of the consequences of the oxidative stress is the non-enzymatic lipid 
peroxidation and it involves the oxidation of fatty acids that occurs in vivo by reactive 
species-mediated reactions [56], being a complex process essentially divided into three 
phases: initiation, propagation and termination (Figure 10) [116]. 
Initiation occurs when a hydrogen is abstracted, or a radical is added to a PUFA 
resulting in oxidative damage. PUFAs are more fragile than saturated fatty acids since 
they have double bonds adjacent to a methylene group (CH2). Once the C-H bond of this 
methylene group is weak, the hydrogen is susceptible of being abstracted. The resulting 
molecule undergoes rearrangement forming a conjugated diene which combines with 
oxygen forming a peroxyl radical, with the ability to abstract one hydrogen from another 
PUFA. This reaction can be catalyzed by metal complexes forming alkoxy radicals (RO•) 
and OH•, which also participate in the lipid peroxidation chain reaction by abstracting a 
hydrogen from the PUFAs. In this way, it is only necessary a starting point for many 
PUFAs being converted to peroxyl radicals (ROO•) initiating the propagation of this chain 
reaction. The resulting radical fatty acids are stabilized by rearrangement into conjugated 
dienes which preserve the most stable products such as hydroperoxides (ROOH), 
alcohols, aldehydes and alkanes. The chain propagates until two radical species conjugate 
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to terminate the chain or until they find an antioxidant that breaks the propagation [56, 
116]. 
The resulting oxidized lipids have bioactivity as vasoconstrictors, vasodilators, 
bronchoconstrictors and may induce the characteristic inflammation of asthma. In 
addition, they have the ability to change the membrane fluidity and consequently its 
associated enzymes and receptors [56]. 
 
Figure 10 – Basic scheme of non-enzymatic lipid peroxidation of a fatty acid. 
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1.3.3 The link between enzymatic and non-enzymatic lipid oxidation of the 
arachidonic acid 
As previously discussed, cys-LTs are biomarkers of asthma [64, 65] and products 
of the enzymatic lipid peroxidation of arachidonic acid [52, 57]. The 8-IsoP is a biomarker 
of non-enzymatic lipid peroxidation mediated by reactive species [117] strongly related 
to asthma [65, 73, 87, 111]. 
Few studies have linked cys-LTs levels to 8-IsoP levels. In a study performed by 
Samitas et al. (2009) [73], a positive correlation (r = 0.61; p < 0.0001) could be observed 
between 8-IsoP levels and cys-LTs in the EBC of asthmatic patients. This correlation 
persisted only in severe asthmatics (r = 0.69; p = 0.044), being an indicator that, in 
addition to reflecting different aspects of inflammation, they are somehow related. 
Baraldi et al. (2003) [118] observed a significant positive correlation between the levels 
of cys-LTs and 8-IsoP (r = 0.62; p = 0.01) in the EBC of children with asthma 
exacerbations although this correlation did not remain significant after treatment with 
steroids (r = -0.14; p = 0.63). Zanconato et al. (2004) [64] obtained a significant positive 
correlation between cys-LTs and 8-IsoP levels (r = 0.47; p <0.01) in the EBC of asthmatic 
children, with different levels of control and severity, who participated in their study. A 
possible explanation is the synthesis of LTC4 regulated by the activity of LTC4 synthase 
and by the amount of intracellular GSH as a substrate. The FceRI-mediated release of 
LTC4 by mast cells, depends essentially on the levels of intracellular GSH, which in turn 
increase with the levels of oxidative stress leading to the aggravation of inflammation 
[60].  
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2.1 From the concept to the experiment 
Metabolomics is an analytical approach defined as an “omic” science dedicated 
to the study of metabolites, which in turn are defined as small dimension bioactive 
compounds (substrates and products, < 1 kDa). They represent the end product of cell 
biochemistry [119, 120] (e.g. ATP, glucose, cholesterol and lipid signaling molecules) 
which involved proteins (proteome) translated from mRNA (messenger RNA; 
transcriptome) transcribed from genes (genome) [121]. These metabolites do not 
comprise static end products of a metabolic cascade but rather a dynamic interplay [122]. 
The complete set of metabolites produced in a cell or tissue at any one time is defined as 
metabolome [123]. Currently, the human metabolome consists of around 114100 known 
metabolites (obtained from “The Human Metabolome Database” version 4.0 – 
http://www.hmdb.ca/ on February 2018). 
The study of metabolites has several approaches which can be defined as 
untargeted or targeted analysis [124]. Untargeted metabolomics includes the metabolite 
fingerprinting, which consists of the identification of metabolite patterns, not necessarily 
involving an extensive identification and quantification of a large set of metabolites since 
multivariate statistical analysis (MVSA) is usually used in order to reduce the dimension 
of data with discriminatory capabilities. The untargeted metabolomics leads to new 
findings and the identification of unexpected metabolites and consequently new 
hypotheses can arise based on findings [122, 124, 125]. On the other hand, targeted 
metabolomics is the identification, quantification and validation of previously discovered 
biomarkers or potential biomarkers of disease or products of a specific pathway or drug 
degradation at any one time. These are hypothesis-based analyzes and include the targeted 
analysis of a single or few metabolites and the metabolomic profile, which is the analysis 
of a large set of metabolites of a cell type, tissue or organism metabolism [121, 122] that 
could be candidate biomarkers discovered in untargeted analysis [126]. Recently, imaging 
techniques are being applied in metabolite profiling. They consist of the spatial 
localization of selected metabolites present in a cell or tissue sample allowing the direct 
observation of the pathological process [120] and include magnetic resonance imaging 
(MRI), positron emission tomography (PET) [127], and mass spectrometry-based 
techniques including, matrix-assisted laser desorption ionization (MALDI), desorption 
electrospray ionization mass spectrometry (DESI), nanostructure-imaging mass 
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spectrometry (NIMS), among others [120, 128], without the need of metabolite extraction 
and separation processes [128]. 
Different metabolomics-based concepts have branched out based on the subject 
of study such as pharmacometabolics – the study of the behavior of drugs in the organism 
based on its metabolomic profile [129]; on the sample such as breathomics – the study of 
the metabolites present in breath [130], for example the studies by Caldeira et al. [131, 
132] with asthmatic children populations; or on the physical state of the metabolites such 
as volatomics – the study of volatile organic metabolites (VOMs) emitted from a cell 
type, tissue or organism present in a variety of matrices or body fluids including urine, 
exhaled breath,  blood, feces and sweat [133]. 
 
2.1.1 The experimental design in metabolomics – the search for biomarkers 
The experimental design in metabolomics epidemiologic studies (Figure 11) 
begins with the selection of the metabolomics approach (targeted or untargeted) and the 
selection of population [134]. If it is intended to include subjects from different groups 
(e.g. control and asthmatic patients), these individuals should be representative of that 
group in terms of number and similarity at the baseline in terms of genetics (i.e. ethnicity, 
gender) age, body mass index, lifestyle (e.g. diet and physical activity), health (disease 
status and medication), since these variables can influence the results [135]. Samples 
should be treated uniformly in terms of sampling, transport, process and storage in order 
to avoid new variables between these factors and minimize changes in the metabolomic 
profile. Fast transport, immediate freezing and the avoid of multiple freeze and thaw 
cycles are vital since some metabolites may deteriorate if enzymatic activity is not 
suspended [134, 136]. 
In order to avoid operator-dependent errors and to obtain the best results possible, 
sample pre-treatment and treatment are fundamental steps in metabolomics, which are 
dependent on the matrix type, properties of the desired metabolites, volume and the 
analytical method that will be used [135]. Despite being less discussed in metabolomics-
themed reviews, sample preparation techniques also play a vital role concerning time, 
cost, ease of use, automation/semi-automation possibility and analytical performance. 
Extracted metabolites are usually separated and characterized through diverse 
metabolomic strategies essentially based on liquid (LC) and gas chromatography (GC) 
hyphenated to diverse spectroscopic techniques [125]. 
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Minimum effort, time, and resources are essential in analytical metabolomics 
studies. Regarding this, method optimization [137] in terms of metabolites extraction 
efficiency and separation, as well as method validation in terms of analytical performance 
including selectivity, linearity, instrumental sensitivity, precision, accuracy, matrix effect 
and extraction efficiency, are essential parameters that need to be taken into account 
during a method development [138, 139]. 
 
Figure 11 – General strategy in a metabolomics epidemiologic study. 
 
Sample characterization, metabolite profiling, fingerprinting as well as correlation 
studies are based on chemometrics (untargeted analysis) and quantitative metabolomics 
(targeted analysis) such as univariate (UVSA) and MVSA in order to identify candidate 
biomarkers of disease [134, 140]. These techniques can be used in screening, diagnosis 
and monitoring of disease progression, leading also to the reduction of disease 
heterogeneity. Thus, being biomarkers precise numbers, they are intended to be reliable 
and valid in terms of specificity, sensitivity and predictive power [141]. Regarding this, 
there is a need for biomarkers with an active role in asthma phenotype/endotype 
identification, diagnosis and treatment, leading to the development of the personalized 
medicine [142, 143]. 
 
2.1.2 Biological samples 
The metabolomics studies in asthma comprise several biological samples 
(biosamples) including urine, exhaled breath, blood, saliva, induced sputum, nasal lavage 
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fluid, BAL fluid and stool. Even though blood (serum and plasma) mostly contains 
endogenous analytes and provides a good overview of the metabolic status of the patient, 
and induced sputum, nasal lavage and BAL fluids are highly relevant to access the airway 
physiology and integrity, they are particularly invasive to obtain and generally require 
trained personnel to make the collection, being relatively inaccessible to obtain [134, 
144]. Therefore, in this section, it is given special attention to biosamples that can be 
collected through totally non-invasive approaches such as (i) urine, (ii) saliva and (iii) 
exhaled breath due to its ease of collection from infants comparatively to the more 
invasive mentioned approaches, and its potential to be used in asthma studies. 
 
 Urine 
Urine is the main way the body eliminates waste and excess products of 
metabolism. It is a transparent, sterile, yellowish-colored fluid produced by the kidneys. 
These organs extract excess products and soluble wastes from the bloodstream resulting 
in a product with high concentrations of urea, inorganic salts, creatinine, ammonia, 
organic acids, toxins and pigmented species such as urobilin inherent to hemoglobin 
degradation, which gives its characteristic color [145]. 
Regarding clinical diagnosis, urine has been used since the ancient Egypt until the 
present times routinely through simple dipstick tests [145] (e.g. human chorionic 
gonadotropin in pregnancy) or through more complex analysis in laboratorial 
environment. 
Urine sampling is a non-evasive procedure which, in opposition to other biological 
matrices, is available in large volumes, requires no previous preparation of the patient, 
and it is easily collected among pediatric ages, for example. In metabolomics studies, 
urine has the advantage of being relatively stable, less complex than other matrices, 
having low concentration of proteins, reflecting the pathophysiological changes in the 
organism, age, sex, among others [134]. To date, 4297 metabolites are known in the human 
urine (obtained from “The Urine Metabolome Database” – 
http://www.urinemetabolome.ca/ on March 2018). Urine also has the advantage of its 
metabolites for volatomics analysis being preconcentrated by kidneys before excretion 
and have reduced matrix effects compared to other biofluids such as blood, resulting in 
better analytical sensitivity even though several substances such as drugs may interfere 
with VOM analysis [133]. Due to these properties, it is believed that urine can be routinely 
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used to identify biomarkers of oxidative stress and inflammation. A volatomics approach 
has first been applied by Linus Pauling et al. in 1971 with the determination of about 280 
volatile substances in a human urine sample [146]. More recently been applied in the 
urine of an asthmatic population by Loureiro et al. [147]. 
The use of urine metabolomics approaches has increased in the past years (Figure 
12). It has been used in the study of asthma [147-150] and also in the study of other 
chronic respiratory diseases such as COPD [149], neurodegenerative diseases such as 
Alzheimer's [151] and Parkinson’s disease [152], different types of cancer such as 
prostate [153] and kidney cancer [154], cardiovascular diseases [155], as well as in the 
determination of urinary excretion of antipsychotics [156] and antidepressants 
metabolites [157], among others. 
 
Figure 12 – Number of publications that include urine in metabolomics studies. Data obtained from 
Clarivate Analytics’ Web of Science, https://clarivate.com/products/web-of-science/, Core Collection 
Database using the following topic search keywords: “urine metabolomics”.  
 
 Saliva 
Saliva is a biological fluid produced by the major (sublingual, submandibular and 
parotid) and several minor salivary glands in the oral cavity. This fluid is mostly 
composed by H2O, inorganic and organic constituents and other substances from the 
airways, food, blood, among others. Water accounts for 99% of saliva components. The 
inorganic constituents (e.g. Na+, Cl- and Ca2+) give to saliva a buffer capacity, tooth 
integrity functions and organic components activity regulation. The organic constituents 
such as urea, lipids and proteins have enzymatic activity (e.g. amylase, lysozymes and 
peroxidases) relevant to oral health, lubrification and digestive functions [158, 159]. 
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This biofluid is readily accessible through easy and non-invasive techniques and 
the exchange of substances between saliva and systemic circulation, through a thin layer 
of epithelial cells, makes it a potential excellent alternative to serum analysis as a source 
of information. Collection of saliva has the advantage of a reduce risk of infection 
compared to serum, the advantage of avoiding privacy and absence issues being able to 
be collected momentarily although in a reduced volume compared to urine. Its 
composition is more stable and not so complex as serum and thus, reflects with more 
accuracy the metabolic condition at any time. In addition it contains metabolites that can 
be used as biomarkers of diseases [159]. To date and according to “The Saliva 
Metabolome Database” – http://www.salivametabolome.ca/ on March 2018), 1236 
metabolites are known in the human saliva. 
Due to its ability to reflect the internal state of the organism [160, 161], saliva has 
become a biosample of interest in forensic analysis [162], occupational pollutants 
monitorization [163] and in metabolomics as a potential diagnostic tool for several 
diseases including, among others, oncological diseases such as breast cancer [164] and 
oral squamous cell carcinoma, periodontal diseases and Sjögren’s syndrome, as reviewed 
by Liu and Duan in 2012 [159]. 
 
 Exhaled breath 
Exhaled breath is mainly composed by a mixture of several inorganic gases (e.g.  
H2O, NO, CO2, CO and O2) VOMs (e.g. saturated and unsaturated hydrocarbons and 
acetone) [110] and non-volatile species (e.g. cytokines, isoprostanes and peroxynitrite), 
from which some are biomarkers of asthma, lung function and airway remodeling [165]. 
Along with urine and saliva, exhaled breath represents one of the most accessible 
biosamples because it is naturally produced in large quantities through the gas exchange 
in the lungs (about 10000 L per day). The potential of breath as a diagnostic tool begun 
with Antoine Lavoisier in 1790 with the study of gas exchange [166]. The modern era of 
breath analysis started with Linus Pauling et al. in 1971 with the determination of about 
250 VOMs in a sample of human breath [146]. Since then, research in the breath analysis 
has been made both in its volatile fraction and in its non-volatile aqueous fraction in the 
form of aerosol particles that can be measured through condensation (i.e. EBC). 
Concentrations of VOMs present in the exhaled breath are a challenge. These 
values are dependent on the concentrations in ambient air, the physiological state of the 
Metabolomics in asthma 
 
37 
 
individual (e.g. age, body mass index and menstrual cycle length), food intake and 
occupational pollutants, as reviewed by Lourenço and Turner [167]. Therefore, the origin 
of the substances detected in breath analysis can be divided into two categories: 
environmental exogenous (environment, food, …) and endogenous (metabolism) 
metabolites. Even though this classification is relatively difficult, endogenous metabolites 
are interesting due to their potential as biomarkers of disease. 
Several breathomics approaches have been applied in the study of diseases 
including, pulmonary diseases such as asthma and COPD [83, 168, 169], oncological 
diseases such as lung, breast, colorectal and prostate cancer [170, 171], and heart failure 
[172]. 
 
2.1.3 Sample preparation techniques in metabolomics – the challenge for 
miniaturization 
The traditional sample preparation techniques are liquid-liquid (LLE) and solid 
phase extraction (SPE). Frequently, these techniques have the disadvantages of not being 
easily hyphenated with an analytical platform, are time consuming, unfeasible sampling 
procedure, needs considerable amounts of harmful organic solvents (e.g. methanol, 
MeOH; acetonitrile, ACN; acetone; and ethanol, EtOH), with strong environmental 
implications, especially in the case of LLE, and requires substantial amounts of sample 
in the range of mL or g [173]. 
Considering this, microextraction techniques (METs) emerged in the early 90’s 
with SPME [174] followed by liquid-phase microextraction (LPME) [175]. Up to date, a 
noteworthy number of different METs are continuously being developed in the field of 
LLE, such as single-drop microextraction (SDME), hollow fiber liquid-phase 
microextraction (HF-LPME) and dispersive liquid-liquid microextraction (DLLME); and 
in the field of SPE including needle-based SPME sampling techniques such as (i) MEPS 
and (ii) fiber SPME [176, 177], in addition to other (iii) microextraction strategies 
(QuEChERS, mSPEed and NTDs) with potential application to the asthma field. 
 
 MEPS 
MEPS is a miniaturized SPE technique consisting of a removable MEPS cartridge 
and a sampler device designed for the characterization of metabolites with different 
properties. The sampler device has the possibility to be manual through a Hamilton gas-
Chapter II 
 
38 
 
tight syringe; semi-automatic by means of a digitally controlled and programmable semi-
automatic device (eVol® XR; Figure 13A) that controls the aspiration/dispensing volume 
and flow rate coupled to a gas-tight XCHANGE® analytical syringe (5-1000 µL; Figure 
13B); and fully-automatic by means of the previous XCHANGE® analytical syringe on-
line with LC or GC autosamplers. The possibility of a semi/fully automation require 
minimal user interference allowing better precision, accuracy and consequently better 
reproducibility. 
 
Figure 13 – An eVol® XR device for semi-automatic MEPS (A) and respective gas-tight XCHANGE® 
analytical syringes (B). 
 
The MEPS cartridge, a metallic cylinder known as “barrel insert and needle” 
(BIN; Figure 14), contains 1-4 mg of a solid packed sorbent bed through which small 
volumes (usually 10-250 µL) of sample and solvent passes retaining and eluting the 
metabolites. Depending on the nature of the metabolites (hydrophobic or hydrophilic) and 
the matrix (aqueous or organic), different sorbent materials are available including silica, 
carbon and polymeric polystyrene-divinylbenzene (PS-DVB) based sorbents [178]. 
Unlike SPE, which only can be used once, MEPS cartridges can be re-used several times 
with human biosamples, such as urine and plasma, without loss of performance reducing 
in this way the costs of extraction [179]. 
Samples used for MEPS purpose, usually require pre-preparation in terms of 
centrifugation, filtration, dilution and the adjustment of pH and temperature in order to 
extend the life of the sorbent and its re-usability and enhance the extraction efficiency 
[178]. MEPS procedure consist of 4 main steps: conditioning/regeneration, sample 
loading, washing and elution, which can be optimized in order to obtain better extraction 
performance in terms of efficiency and matrix effect. The conditioning/regeneration of 
the sorbent is performed with an organic solvent followed by its equilibration with H2O 
(pure or acidified) before loading the sample and ends with the elution followed by the 
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regeneration of the sorbent that match with conditioning step if further extractions are 
made. Sample loading cycles consists of a certain number of drawing up into the syringe 
and discharge. Washing the fiber with H2O (pure or acidified) allows the removal of 
undesired matrix interferences that can be weakly retained on the sorbent while the elution 
step consists on the use of the best solvent and the lowest volume possible that is able to 
elute the target analytes retained on the surface of the sorbent [178-180]. 
 
Figure 14 – MEPS BIN (barrel insert and needle) and schematic magnification of a MEPS BIN. 
Magnification illustrate an analyte adsorbed on the sorbent particles. Adapted from  [178]. 
 
The use of MEPS procedure has increased (Figure 15) since it was firstly purposed 
by Abdel-Rehim in 2004 for determination of local anesthetics in human plasma [181]. 
Even though MEPS procedure was only applied once in the study of asthma by Perestrelo 
et al. [61] on the characterization of urinary LTB4 (Table 4), it has been applied in the 
study of other diseases such as cardiovascular diseases [155] breast and lung cancer [182, 
183] as well as other fields such as pharmacology, in the study drugs behavior including 
psychoactive metabolites in oral fluid [184] or urine [156, 157], toxicology [185], food 
chemistry [186], among others. 
 
 SPME 
In 1990, Arthur and Pawliszyn [174] developed the first successful MET called  
SPME. This technique had several advantages over the mentioned classical sample 
preparation techniques including the absence or minimum requirement of solvents, the 
need for small amounts of sample, short sample preparation time, possibility for 
laboratory automation and on-site sampling. 
 
  
Table 4 – Microextraction techniques used in the study of asthma biomarkers. Abbreviations: MEPS – microextraction by packed sorbent; HS-SPME – headspace-solid-phase 
microextraction; DVB/CAR/PDSM – divinylbenzene/carboxen/polydimethylsiloxane; VOM – volatile organic metabolite; ANOVA – analysis of variance; PLS – partial least 
squares; PLS-DA – partial least squares-discriminant analysis; UHPLC-PDA – UHPLC-photodiode array; GC×GC-ToFMS – two-dimensional gas chromatography–time of flight 
mass spectrometry; GC-qMS – gas chromatography-quadrupole mass spectrometry; NMR – nuclear magnetic resonance spectroscopy. 
Extraction 
platform 
Stationary phase Analytical 
platform 
Biosample Population Groups Analyte Statistical 
analysis 
Comments Ref. 
MEPS Porous graphitic 
carbon 
UHPLC-PDA Urine Adults and 
children 
Case vs 
control 
Targeted LTB4 - Increased in asthmatics. 
LOD = 0.37 ng/mL 
LOQ = 1.22 ng/mL 
[61] 
HS-SPME DVB/CAR/PDMS GC–qMS Exhaled 
breath 
Children Case vs 
control 
Untargeted. 44 identified 
VOMs present only in 
breath 
ANOVA and 
PLS-DA 
28 VOMs with 
discriminatory power. 
Asthmatics characterized 
by VOMs linked to 
oxidative stress such as 
alkanes and aldehydes 
[131] 
HS-SPME DVB/CAR/PDMS GC×GC-ToFMS Exhaled 
breath 
Children Case vs 
control 
Untargeted. Full set of 
134 VOMs identified 
PLS-DA and 
Monte Carlo 
cross 
validation 
23 VOMs with 
discriminatory power. 
Asthmatics characterized 
by VOMs linked to 
oxidative stress belonging 
to alkanes 
[132] 
HS-SPME DVB/CAR/PDMS GC×GC-ToFMS Exhaled 
breath 
Adolescent 
swimmers 
Case vs 
control 
Untargeted. Hundreds of 
VOMs identified. 
Targeted 5 aliphatic 
alkanes and 3 aldehydes 
linked to oxidative stress 
PCA Swimming associated to a 
decrease in oxidative stress 
VOM levels. 
More pronounced in 
controls 
[190] 
HS-SPME DVB/CAR/PDMS GC×GC-ToFMS Urine Adults Case Untargeted. Several 
dozen VOMs identified. 
Targeted 34 aliphatic 
alkanes and aldehydes 
PLS Metabolites associated to 
eosinophilic inflammation, 
lung function and disease 
severity 
[147] 
HS-SPME DVB/CAR/PDMS GC×GC-ToFMS 
and 1H-NMR 
Urine Adults Case Targeted aldehydes and 
alkanes. Untargeted 1H-
NMR 
PCA Oxidative stress 
(aldehydes, alkanes, 
carnitine, acetylcarnitine) 
Tricarboxylic acid cycle 
metabolites (e.g. citrate, 
alanine) linked to 
exacerbations 
[148] 
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When it was first introduced, this technique involved a fused silica fiber coated 
with polyimide inside a Hamilton gas-tight syringe. This syringe was intended to protect 
the fiber and also allow the introduction of the fiber into a GC injector. Currently, 
commercial SPME consists of a syringe-like device containing a fiber assembly and a 
fiber assembly holder, which can be manual or automated (Figure 16A). The fiber 
assembly includes a fiber coated with 1 to 2 cm of different polymeric stationary phases 
to extract and concentrate the analytes from the sample protected into a needle. The 
manual fiber assembly holder, consists of a plunger with a spring, a stainless-steel tube 
and an adjustable depth gauge [173]. 
 
Figure 15 – Number of publications that include MEPS as a tool in metabolomics studies. Data obtained 
from Clarivate Analytics’ Web of Science, https://clarivate.com/products/web-of-science/, Core Collection 
Database using the following title search keywords: “microextraction in/by packed sorbent/syringe”. 
 
Depending on the nature of metabolites, matrix and the purpose of the analysis, it 
is necessary to optimize different device and sample pre-treatment parameters that 
influence the analytical performance of the method [173, 180]. 
 
Device parameters 
The device parameters with influence in the extraction performance includes the 
extraction mode, nature of the fiber (coating), agitation method and extraction time [173, 
180, 187, 188].  
The extraction of metabolites from a gaseous sample, liquid or solid, can be 
performed in two ways, via headspace-SPME (HS-SPME) mode, in which the fiber is 
exposed to the gas phase above the sample (Figure 16B), or by direct immersion (DI)-
Chapter II 
 
42 
 
SPME in which the fiber is directly immersed into the liquid sample. The co-extraction 
of non-volatile interferences (e.g. proteins) can complicate the extractive process in 
complex bio-samples such as urine, requiring, in some cases, the introduction of barriers 
in the form of porous membranes between the sample and the fiber (membrane-protected 
SPME) or in the form of a gaseous space between the sample and the fiber (headspace; 
HS-SPME) allowing a greater selectivity as well as a good sensitivity for the extraction 
of volatile compounds [173, 180, 188]. 
 
Figure 16 – Schematic overview of a (A) commercial SPME with manual fiber assembly holder, and (B) 
representation of a headspace-solid-phase extraction. Adapted from [173, 189]. 
 
The selection of the fiber coating is important since it influences the selectivity 
and sensitivity of the extraction. Different fibers are commercially available consisting of 
different materials such as fused silica and metal alloy coated with several stationary 
phases composed by one, two or three polymers with different film thickness (7 to 100 
μm) and lengths (1 to 2 cm), which adsorb/absorb and concentrate the metabolites by 
partition between the matrix and the coating during the extraction. Fibers coated by a 
single-polymer (liquid) have absorption as the extraction mechanism. They may be 
nonpolar such as polydimethylsiloxane (PDMS), suitable for the extraction of nonpolar 
analytes, or polar such as polyacrylate (PA) and carbowax-polyethylene glycol (PEG) 
suitable for the extraction of highly polar compounds. Those of mixed-polymer (solid) 
have the adsorption as extraction mechanism, have bipolar properties, are available for 
the extraction of low molecular weight analytes possessing a wide range of 
physicochemical properties and include the polydimethylsiloxane/divinylbenzene 
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(PDMS/DVB), carboxen/polydimethylsiloxane (CAR/PDMS), and the divinylbenzene/ 
carboxen/polydimethylsiloxane (DVB/CAR/PDMS) [173]. 
Agitation of sample by ultrasound and/or magnetic stirring, promotes the diffusion 
of the analytes from the bulk matrix, by mass transfer, to the fiber, thereby reducing the 
time to reach equilibrium. The more efficient the agitation, the shorter the time required 
to reach the equilibrium and the greater the amount of analyte extracted under non-
equilibrium conditions. 
Extraction time is one of the most important parameters since it is important to 
reach the equilibrium between the analytes in the matrix and in the fiber coating without 
degrading the sample. In HS-SPME mode, incubation time is also important since the 
equilibrium between the matrix phase and the headspace needs to be reached [173, 180, 
187, 188].  
 
Sample pre-treatment parameters 
The sample pre-treatment with influence in the extraction efficiency include the 
sample temperature, volume, pH and ionic strength [173, 180, 187, 188].  
A high temperature improves the extraction rate by decreasing the metabolites 
fiber coating–sample matrix distribution constant even though it can decrease the amount 
of extracted metabolite, sensitivity, precision and lead to sample degradation.  
Higher sample volumes lead to an increase on the total amount of extracted 
analytes. It is generally compromised by the size of the vial or by the amount of sample. 
SPME fibers only extract analytes in their neutral form. pH adjustments of the sample, 
between the limits of the fiber, provide the selectivity of the technique by interfering with 
the ionization state of the compounds. A low pH promotes the extraction of the acidic 
compounds while a high pH promotes the extraction of the basic compounds. The ionic 
strength of the sample is higher with the addition of soluble salts – salting-out effect. This 
causes a decrease in the solubility of many organic compounds, except for those highly 
polar, simplifying their diffusion from the sample to the headspace. 
SPME has been applied in the study of asthma. Table 4 describes some studies of 
SPME-asthma related. Furthermore, this strategy has been adapted and applied in 
pharmacotherapeutic analysis, forensics, clinical diagnosis and environmental pollutants 
exposure, among others, as reviewed by Kataoka and Saito in 2011 [188]. 
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 Recent microextraction techniques with high potential application to 
asthma field 
The challenge for more efficient and environmentally friendly techniques is a 
continuous process. Recently, it has given rise to modifications of already existent 
techniques including the dispersive “quick, easy, cheap, effective, rugged and safe” 
(QuEChERS) with µ-QuEChERS [191], SPE upgraded to MEPS [178, 192] and more 
recently to µSPEed® [193]. The concept of fiber SPME gave rise to other extraction 
techniques suitable for the extraction of metabolites present in a gaseous phase. Regarding 
this, a needle-based extraction technique named needle trap device (NTD) emerged as an 
exhaustive active sampling procedure with the simplicity of SPME [173]. 
QuEChERS is an extraction and clean-up technique developed in 2003 by 
Anastassiades et al. [194] for the characterization of pesticide residues in vegetables and 
fruits. Briefly, in their work, they used a single-phase extraction of 10 g of sample with 
10 mL of acetonitrile (ACN) followed by a salting-out extraction step with MgSO4 and 
NaCl and a dispersive SPE clean-up step with primary-secondary amine (PSA) and 
MgSO4. Since QuEChERS is a versatile extraction technique, it can be optimized 
essentially in terms of salts (e.g. citrate and acetate buffers), extraction solvents and 
extraction type (e.g. ultrasound and vortex) in order to fulfill the different analytical 
needs. More recently, this technique has suffered miniaturization in terms of amount of 
sample, salts and solvent from g and mL to mg and µL allowing the analysis of small 
sample amounts – µQuEChERS. This MET has not been used in pathological studies but 
has been used for the analysis of pesticide residues present in different matrices such as 
gastropods and arthropods [195], tissues such as rat brain and liver [196], biofluids such 
as rat blood [196], micotoxins in cereals [191], organic pollutants in human urine [197], 
among others. 
MEPS is a multipurpose technique that had a technological upgrade with the arose 
of µSPEed® [193]. This downscaled MEPS technique distinguishes itself by the direct 
flow through the cartridge into the syringe barrel by means of a micro one-way valve. 
Under controlled conditions, the sample is then pushed through the sorbent allowing the 
analytes to be concentrated onto the top of the sorbent bed. Even though it has a strong 
potential since it allowed the reduction of the dead volume, the elution solvent needed 
and the reduction of the particle size from 30-50 µm, used in SPE and MEPS, to less than 
3 µm which is an improvement in terms of extraction and elution efficiency and 
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sensitivity. This strategy was recently used by Porto-Figueira et al. for the analysis of 
phenolic compounds in teas [193]. 
Over the years, different types of needle-based sampling techniques were 
developed. Although the first report about a needle filled with a sorbent bed for trapping 
volatile compounds from air was described in 1978 by Raschdorf [198], needle-based 
extraction devices have only recently become popular due to SPME and SPE. The 
demand for a more robust technique, gave rise to an in needle packed sorbent format, the 
needle trap device (NTD) introduced by Pawliszyn et al. in 2001 [199]. While SPME has 
a higher efficiency extracting less or semi-volatile free metabolites, NTDs are suitable for 
the extraction of highly volatile and particle-bound metabolites [173, 200]. This strategy 
is a promising sampling platform distinguished by having an exhaustive active extraction 
nature that results in a total concentration information rather than free concentration 
information provided by other METs such as SPME. The NTD technique allows us to 
collect, prepare and introduce the analytes in just one step simplifying all the process 
maintaining the sensitivity and eliminating the time and expendable large volumes [200, 
201]. Different variants of NTDs are commercialized by PAS Technology (Magdala, 
Germany) and Shinwa Chemical Industries Ltd. (Kyoto, Japan) thus, NTDs with different 
combinations of sorbent, lengths, gauges, side hole and tips can be acquired for a 
particular purpose. This MET has been used in the analysis of volatile analytes present in 
the breath of heart failure patients [202], breath of healthy, smoking and nonsmoking 
individuals [203], air pollutants (aldehydes) [204], headspace VOMs of whole blood 
[205], among others. 
 
2.1.4 Chromatographic techniques – metabolite characterization strategies 
An appropriate analytical platform must be selected in order to perform the 
characterization of the extracted metabolites. With the advance of technology, detection 
techniques, including mass spectrometry (MS), nuclear magnetic resonance (NMR), 
ultraviolet-visible (UV-Vis) and fluorescence detections (FD), required to detect, 
identify, and quantify metabolites, had made remarkable improvements regarding 
analytical sensitivity along with the development of the separation techniques such as LC 
with the emergence of ultra-high performance liquid chromatography (UHPLC) and GC, 
both with the possibility of automation ease of use and costs reduction [125, 145] leading 
Chapter II 
 
46 
 
to the possible analysis of metabolites in trace concentrations in non-invasive samples 
such as urine, saliva and exhaled breath. 
Even though NMR being a powerful detection technique that allows the 
simultaneous analysis of several metabolites without comprising the integrity of the 
sample/extract, it is considered of low sensitivity relatively to its counterparts and thus, 
used to detect and quantify the main metabolites of an extract allowing its recovery for 
further analysis. Therefore, NMR is used as a mandatory complement to more sensitive 
techniques such as MS detection [121, 125]. 
Below it is described the most commonly chromatographic approaches used in 
metabolomics: (i) LC and (ii) GC. 
 
(i) Liquid chromatography 
LC is usually chosen to characterize more polar and less volatile or non-volatile 
metabolites [206]. LC-based approaches are among the most widely used analytical 
platforms in metabolomics and one of the most important tools regarding detection, 
identification and validation of disease biomarkers [207]. 
In order to obtain short analysis times and high analyte separation, over the past 
years we have seen an evolution in terms of particle size (< 2 µm), and particle technology 
such as porous, solid and particles with a solid core and a porous shell particle. 
Considering this, instruments capable of tolerating the extreme pressures generated were 
required, due to the increased theoretical plates (van Deemter equation), which could 
reach around 18000 psi. With this in mind, UHPLC emerged in order to respond to the 
most recent needs of analytical chemistry and to make an upgrade to its ancestor, the 
HPLC, in terms of resolution, sensitivity and speed of analysis, which is particularly 
important when developing a method [208]. A schematic of a UHPLC apparatus is shown 
in Figure 17. 
In the 1970’s, a few years after LC hyphenated with a ultraviolet (UV) detector 
being in use for metabolite studies [209], liquid chromatography-mass spectrometry (LC-
MS) begun to be used [210]. Currently, due to its higher sensitivity (i.e. limit of detection, 
LOD < 1 pg) above other detection techniques [211], MS is the metabolomics detection 
tool by excellence after separation by LC [207]. The miniaturization of the sample 
treatment techniques and their improvement in terms of sensitivity has allowed the use of 
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absorbance detection techniques [178] such as photodiode array (PDA) and UV at a 
relative reduce cost compared to MS. 
 
Figure 17 – Schematic diagram of an UHPLC system. 
 
After isolation, extracts usually do not need further treatment, even though 
sometimes, they can be reduced or completely evaporated under a gentle nitrogen stream 
and resuspended in mobile phase [156]. Depending on the nature of the extracted 
metabolites, different parameters could be optimized in order to obtain the best resolution 
and analytical performance possible. Among these parameters, it is highlighted the 
column selection, column temperature, flow rate of the elution solvents and gradient. 
 
(ii) Gas chromatography 
GC is an analytical strategy frequently selected to characterize volatile or 
“volatizable” metabolites [206]. Compared to LC, this separation technique has a higher 
chromatographic resolution being an advantage on the analysis of trace amounts of 
analytes [121]. 
Even though there are different GC detectors, in this section it will be given special 
attention to the gas chromatography-mass spectrometry (GC-MS) configuration due to its 
wide applicability. Basically, all GC-MS share the same essential components: an 
injector, to allow the sample to get into the column system; a detector; and a gas 
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chromatograph, which connects a column to the injector and to the detector. Metabolites 
are separated by their interaction with the column (stationary phase), housed into a 
thermostated oven, which regulates the temperature on which the separation is made (e.g. 
isothermal or programmed). The elution is further made by means of a carrier inert gas 
(mobile phase) such as helium or hydrogen controlled through a flow/pressure regulator. 
The interface module connects the column to the detector where an ion source ionizes 
and fragments the metabolites subsequently detected by a mass analyzer before its output, 
data is selected, controlled and processed into a chromatogram [212]. A schematic 
diagram of a GC-MS apparatus is shown in Figure 18. 
The GC-MS begun to be used in the middle 1960’s for metabolite studies [213]. 
Currently, this platform is the most widely used chromatographic technique for the 
characterization of VOMs due to its high resolution and cost comparatively to its liquid 
counterpart. Metabolites are obtained from a volatile fraction of the sample (i.e. HS) or 
through derivatization of non-volatile metabolites. In order to improve the number of 
detected metabolites (i.e. number of peaks) and sensitivity, two-dimensional gas 
chromatography (GC×GC) appeared as an upgrade to the analytical platform. Metabolites 
separated on a column are separated a second time on a second column with different 
properties [125]. 
 
Figure 18 – Schematic diagram of a GC-MS system. 
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In addition to the advances that have been made in terms of sensitivity and 
resolution of the analytical platforms, the most recent improvements in chromatography 
include the coupling of two separation techniques such as LC to GC greatly increasing 
the separation efficiency at two different states at the same time large amounts of solvents 
are introduced into a GC column [214]. 
 
2.1.5 Statistical methods in metabolomics analysis 
Data analysis comprises the statistical treatment of the data obtained from the 
previous experimental steps. Depending on the purpose, it can be performed either on 
normalized metabolite values including their areas or concentration values obtained 
through the application of the regression equation (data preprocessing), generally used in 
MVSA, or directly on the values obtained without normalization frequently used in 
UVSA. 
Statistic data analysis can be branched mainly in UVSA and MVSA. UVSA is the 
statistical analysis of one variable at once while MVSA analyzes many variables at once. 
UVSA tests are performed in order to group differences such as metabolite mean values 
(e.g. healthy control group versus asthmatic group) for instance. It includes both 
parametric tests such as dependent/independent t-test and analysis of variance (ANOVA) 
tests, and non-parametric tests such as Mann-Whitney, Wilcoxon signed-rank, Kruskal-
Wallis and Friedman’s, which can be easily applied to data obtained from the analytical 
platform [215]. MVSA is an essential tool for the analysis and interpretation of high-
throughput metabolomics generated from untargeted and multitargeted analysis [216]. As 
part of the metabolomics, MVSA analysis can be applied through two different strategies, 
chemometrics and quantitative metabolomics. Chemometrics is used in untargeted 
analysis and can be automated, statistical analysis is performed directly on spectral 
patterns and signal intensity, and metabolites are identified at the end while in quantitative 
metabolomics, metabolites are identified first, and data is analyzed after its preprocessing. 
Even though they serve two different purposes, they share the same statistical methods 
[140]. 
Statistical models can be unsupervised or supervised. Unsupervised models 
(unlabeled data) allow us to discover patterns, groups and outliers within data and include 
principal component analysis (PCA), a powerful statistical technique that has the 
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capability to reduce a high-dimensional dataset into principal components keeping the 
maximum of variability. By plotting the first two or three principal components that 
explain the total variance (scores plot), it is given a graphical visualization of the 
separation between groups and by plotting variables (loadings plot) on the same diagram, 
it can be concluded which variables accounted for the separation and to which group they 
belong [217]. Other unsupervised statistical models include clustering methods such as 
K-means and Hierarchical clustering and Self-organizing map [134, 140]. Supervised 
models (labeled data) are useful to explore which metabolites have discriminatory power 
regarding disease, disease phenotypes/endotypes and prediction, allowing the 
identification of biomarkers and include stepwise linear discriminant analysis (SLDA), 
which forms a number of orthogonal linear discriminant functions equal to the number of 
dependent variables minus one. This method has the ability to minimize the variance 
within groups and maximize the variance among groups [218]. Other supervised 
statistical strategies include partial least squares (PLS) methods (e.g. PLS-discriminant 
analysis, PLS-DA; and orthogonal PLS-DA) [219] and support vector machine [134, 
140]. 
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3.1 Introduction 
Asthma, one of the major noncommunicable diseases, is a potentially serious 
chronic disease usually characterized by chronic airway inflammation, bronchial 
hyperresponsiveness and recurrent episodes of reversible airway obstruction. It is defined 
by the history of respiratory symptoms such as cough and wheezing, shortness of breath 
and chest tightness that vary over time in their occurrence, frequency and intensity, with 
variable expiratory airflow limitation due to bronchoconstriction (airway narrowing), 
airway wall thickening and increased mucus [220]. The symptoms may be triggered or 
worsened by a combination of host factors including genetic predisposition, gender and 
ethnicity, with environmental factors such as viral infections, indoor and outdoor 
allergens, tobacco smoke, air pollution, food additives, exercise, stress and emotions, 
among others. According to the Global Asthma Report (2014) [2], is estimated that 300 
million people of all ages in all parts of the world currently are affected. Its prevalence is 
increasing in many countries and especially in children. Asthma is associated with a high 
disease burden at both social and economic level. Adverse social impacts include: (i) 
reduced self-confidence, (ii) decreased quality of life, (iii) time lost from work or 
education, and (iv) social stigma, whereas the economic burden is due to direct costs 
(hospital admissions and medication) and indirect medical expenses, including 
productivity losses and school absenteeism [3]. Asthma is particularly problematic given 
that the disease consists of many variants, each with its own etiologic and 
pathophysiologic factors, including different cellular responses and inflammatory 
phenotypes. Thus, asthma is not considered a single disease, but a multifaceted syndrome 
which turns its diagnosis extremely difficult [221]. 
Its diagnosis is based on history and patterns of symptoms; physical examination; 
measurements of lung function and measurements of allergic status to identify risk 
factors. In order to improve the diagnosis and treatment of the different asthma subtypes, 
especially those which are more severe and therapy resistant, considerable research 
efforts has been made in recent years aimed at revealing biomarkers capable to 
discriminate different phenotypes of the disease [222].  
Currently, biomarkers for asthma are found in several biological fluids which can 
be assessed by distinct sampling methodologies of the lower airways, meeting at least, 
some of the above mentioned criteria: invasive sampling (BAL, submucosal or 
transbronchial biopsies), semi-invasive (induced sputum), minimally invasive (blood) 
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and totally non-invasive (saliva, exhaled breath and urine) [223]. Invasive sampling 
techniques have been largely substituted by other less invasive as they may require 
complicated and extremely invasive techniques, hard to use as a routine diagnostic tool, 
particularly in children. In turn, sputum induction is a validated method for an asthma 
diagnosis, corresponding to a safer procedure, cheaper and generally easier to perform 
than bronchial biopsy or BAL, although more troublesome than exhaled breath. Further, 
the interest in saliva studies in relation to asthma is still preliminary and the role of many 
possible confounders needs to be considered [223]. On the other hand, potential 
biomarkers have been measured and characterized in EBC. However, this sampling 
technique still awaits standardization before it can be reliably implemented into clinical 
practice [224]. In fact, the lack of validation of such sampling techniques and the 
heterogeneous nature of the inflammatory response has boosted the development of new 
non-invasive airways sampling methods, and the determination of adequate biomarkers 
[86, 221]. 
Asthma biomarkers obtained using non-invasive sampling procedures are 
especially appealing for young patients, despite issues with dilution and sensitivity [86]. 
For body fluids such as urine, samples are easily obtained and possess an array of 
molecular biomarkers related to airway inflammation. Urinary levels of arachidonic acid 
metabolism end products, have revealed potential phenotype-specific biomarkers in 
asthma [225]. Oxidation of arachidonic acid is a fundamental enzymatic lipid 
peroxidation reaction that leads to the formation of bioactive eicosanoids such as PGs and 
LTs, which are key mediators of bronchial inflammation and response modulation in 
airways [226]. These metabolites can not only be used as asthma biomarkers, but also in 
the evaluation of disease progression and follow of the therapy efficiency [86, 222]. 
The major asthma-related PGs and LTs metabolites were previously measured in 
urine by means of radioimmunoassay or enzyme immunoassay [227] and then, by 
reversed phase LC after pre-column extraction combined with radioimmunoassay [228]. 
Still, spectroscopic techniques corresponded to the standard technological approach to 
measure the urine metabolome [229, 230], which, in combination with LC is useful to 
distinguish asthma severity subtypes [231, 232]. 
Subsequent studies performed on patients with persistent asthma also assayed 
urinary LTs levels by MS for disease risk assessments and therapy purposes [233, 234]. 
In 2016, Loureiro et al. [147] examined the relationship between oxidative stress 
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extension, eosinophilic inflammation, and disease severity using SPME followed by a 
two-dimensional gas chromatography coupled to mass spectrometry with a high-
resolution time-of-flight analyzer (GC×GC-ToFMS). Other approaches to screen urinary 
LTs based on LC tandem MS (LC-MS/MS) method were also reported [235]. 
The detection of eicosanoid metabolites in urine has provided insights into the 
inflammatory and oxidative stress status of asthmatic patients. However, constraints 
related with population sample sizes and intrinsic sample variability of urine samples 
have affected the accuracy of the analytical approaches so far. 
METs emerged in the 90’s with SPME [173, 174] and up to date, a noteworthy 
number of different METs are continuously being developed including needle-based 
sampling techniques such as MEPS [177], a miniaturized SPE technique consisting of a 
removable cartridge containing a sorbent, and a syringe-like sampler device, which can 
be manual, semi-automatic or fully automatic [178]. 
Taking into consideration the most recent trends in LC, UHPLC has been widely 
spread due to its increased sensitivity, ultra-resolution and ultra-fast analysis. Therefore, 
the present work aimed to develop an improved and highly sensitive MEPS/UHPLC-
based approach, to identify and quantify lipid peroxidation biomarkers related with 
asthma – LTs E4 and B4 and 11βPGF2α – present in urine of asthmatic patients and healthy 
individuals. The most extraction efficiency-influencing experimental parameters, 
including the sorbent material, the number and mode (extract-discard and extract-eject) 
of sample loading cycles, the pH, the volume of elution solvent and the conditioning 
solvent, were evaluated and optimized by means of a univariate experimental design. In 
addition, important instrumental parameters with influence on the chromatographic 
resolution, such as composition of the mobile phase, the nature of the stationary phase of 
capillary column and the flow rate of mobile phase, were also optimized. The stability of 
eicosanoids extracts was checked over a period of 24 hours with sampling throughout a 
single day. The proposed methodology was applied to the analysis of children urine with 
allergic asthma and healthy children, used as control group. 
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3.2 Materials and methods 
 
3.2.1 Reagents and materials 
All standards and reagents were of analytical grade with a purity higher than 98%. 
ACN (99.9%) and MeOH (99.9%) were obtained from Fisher Scientific (Leics, UK). 
Formic acid (FA; 98%), EtOH (99.5%), calcium chloride-2-hydrate, sodium sulfate 
anhydrous, sodium carbonate anhydrous, potassium di-hydrogen phosphate and sodium 
hydroxide (NaOH) were acquired from Panreac (Barcelona, Spain). Magnesium chloride-
6-hydrate and potassium chloride were purchased from Honeywell Riedel-de-Haën AG 
(Seelze, Germany). Tri-sodium citrate-2-hydrate and ammonium chloride were acquired 
from Merck (Darmstadt, Germany) and sodium chloride from Sigma-Aldrich (Buchs, 
Switzerland). Ultrapure H2O (18 MΩ cm at 23 °C) was prepared using a Milli-Q water 
purification system (Millipore, Milford, MA, USA). Kaempferol, used as internal 
standard (IS), was acquired from Fluka Biochemica AG (Buchs, Switzerland). LTB4, 
LTE4 and 11βPGF2α standards were acquired from Cayman Chemical Co. (MI, USA). 
The eVol® XR hand-held automated analytical syringe (500 μL) and the BINs: 
C18, C8, C2, SIL, M1, HLB-DVB, R-AX and R-CX, containing the sorbent used in the 
microextraction procedure were purchased from SGE Analytical Science Europe, Ltd. 
(Milton Keynes, United Kingdom). The polymeric sorbents PEP, VAX and PGC were 
from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). 
The capillary columns and pre-columns: Acquity UPLC® BEH C18 (2.1 × 50 mm) 
protected with an Acquity UPLC® BEH C18 VanGuard™ Pre-column (2.1 × 5 mm), 
Acquity UPLC® HSS T3 (2.1 × 100 mm) protected with an Acquity UPLC® HSS T3 
VanGuard™ Pre-column (2.1 × 5 mm), Acquity UPLC® CSH C18 (2.1 × 150 mm) 
protected with an Acquity UPLC® CSH C18 VanGuard™ Pre-column (2.1 × 5 mm) and 
CORTECS UPLC® C18 (2.1 × 100 mm) protected with a CORTECS UPLC® C18 
VanGuard™ Pre-column (2.1 × 5 mm), were acquired from Waters Portugal (Lisboa, 
Portugal). The Kinetex® HILIC (2.1 × 100 mm) protected with SecurityGuard™ ULTRA 
cartridge for HILIC UHPLC (2.1 × 2 mm) was supplied by Tecnocroma – Técnicas 
analíticas, LDA (Caldas da Rainha, Portugal). 
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3.2.2 Standard solutions and synthetic urine 
Individual solutions of all standards were prepared in EtOH. The LTB4 and LTE4 
were prepared at 10 µg mL-1 directly as working solutions and the 11βPGF2α and the IS 
at 1 mg mL-1 as stock solutions. The 11βPGF2α and IS working solutions were diluted in 
EtOH at concentrations of 100 µg mL-1 and 1 µg mL-1, respectively. All stocks and 
working solutions were aliquoted in 2-mL amber glass vials and stored at -80 ℃. 
A synthetic urine (SU) solution was prepared according to Wilsenach et al. [236] 
with slight modifications (Table 1A, Annex I). Urea was not used due to possible 
degradation (interferent peaks). Creatinine was not used due to a possible normalization 
of the targeted analytes to this compound. Prior to its use, the pH of the SU was adjusted 
to 5.1 (Mettler Toledo™ EL20 Benchtop pH Meter for Teaching and Learning, Mettler 
Toledo AG, Switzerland) with 10% FA or 1M NaOH, and filtered through a 0.2 µm 
membrane PTFE filter (Merck Millipore, Milford, MA, USA). The pH of real urine 
samples including an unspiked real urine (USRU), were adjusted to 5.1, centrifuged at 
5000 rpm (2739 × g; Sigma 3K30, Sigma Laborzentrifugen GmbH, Germany) for 15 min 
at 5 ℃, and the supernatants filtered through 0.22 µm PTFE syringe filters (BGB 
Analytik, VA, USA). 
For method development, optimization and validation, the assays were carried out 
using fortified SU with LTB4, LTE4 and 11βPGF2α at different concentrations according 
to the sensitivity of the UHPLC-PDA and the amount of eicosanoids present in urine. 
The stability of the extracts was evaluated in extracts of spiked SU at low level 
(LL) and medium level (ML) of concentrations. A set of 4 replicates were taken and 
analyzed at 0, 8, 16 and 24 hours after extraction. This parameter, evaluated by comparing 
the concentration at each time compared to the concentration at time 0, was calculated as 
follows: 
 
Stability (%) = (Ati/At0) × 100 
 
where Ati represents the analyte concentration measured at the specific time and At0 
represents analyte concentration measured immediately after MEPS procedure (0 hour), 
time point zero. This parameter allowed us to know how long the eluates can be in the 
sample manager chamber before analysis without compromising the integrity of the target 
analytes. 
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3.2.3 Sample collection and preparation 
This study was performed in accordance with the principles contained in the 
Declaration of Helsinki and approved by the Ethical Committee for Health of Funchal 
Hospital (SESARAM, EPE; Annex II) and by Regional Direction of Education (DRE; 
Annex III). All tutors of the subjects were informed about the purpose of the study (Annex 
IV) and signed an informed consent to participate in the study (Annex V). 
Asthmatic children diagnosed with uncontrolled symptoms (N = 27, age = 8.8 ± 
4.6Y) were recruited in the emergency and allergology service of Funchal Hospital, while 
urine samples from healthy children (N = 17, age = 7.8 ± 1.4Y) were collected at two 
schools, EB1/PE Tanque – Monte and EB1/PE Visconde Cagongo in Funchal, Portugal. 
Relevant information for the study including gender, age and other information such as 
familiar diseases, home characteristics, type of disease including clinical data (controlled 
or not controlled disease, and clinical symptoms), therapies, among others, was obtained 
at sample collection (Table 5) through a brief questionnaire (Annex VI for children from 
hospital and Annex VII for children from schools). 
No restrictions in terms of diet and urine sample (e.g. first morning sample) were 
applied to the individuals. Each individual, healthy or asthmatic patient, provided a urine 
sample in a 100-mL urine beaker with integrated transfer device (Greiner Bio-One 
GmbH, Austria). Samples were transported to the laboratory in a portable cooling box, 
suitable for this kind of biological samples, aliquoted in 8-mL glass vials and immediately 
frozen at -80 ℃ in order to quench any rapid degradation activity such as oxidation of 
labile metabolites as well as various enzymatic reactions. Compared with other biofluids, 
urine offers several advantages since it is obtained through an easy and totally non-
invasive sampling procedure, may be collected across all ages even in severe patients, is 
a rich source of metabolites and its composition reflects the imbalances of all biochemical 
pathways within the body. 
 
3.2.4 Isolation of targeted analytes by MEPS 
The targeted analytes, LTB4, LTE4 and 11βPGF2α, were isolated from urine using 
a semi-automatic miniaturization of SPE, the MEPS. This off-line procedure combines a 
digital and programmable semi-automatic device (eVol® XR) that controls the 
aspiration/dispensing volume and flow rate with minimal user interference allowing 
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greater precision and accuracy and consequently greater reproducibility; a 500-µL gas-
tight analytical syringe; and a removable MEPS cartridge, known as “barrel insert and 
needle” (BIN), containing 1-4 mg of a solid packed sorbent bed. This experimental 
procedure includes: (i) an activation process of the sorbent with H2O and MeOH, (ii) the 
conditioning of the sorbent usually performed with the elution solvent, (iii) the sample 
loading where the sample is forced to pass through the sorbent bed several times, in order 
to efficiently retain the analytes of interest, (iv) a washing step to remove unwanted 
analytes not retained in the sorbent; and finally (v) the elution where the analytes were 
eluted using an appropriate solvent [178]. A SU sample spiked at 40 ng mL-1 for the LTB4 
and LTE4, and 160 ng mL-1 for the 11βPGF2α, was used in the optimization of the 
experimental parameters with influence on the MEPS efficiency. The chemical nature of 
the sorbent material, the number and mode (extract-discard and extract-eject) of sample 
loading cycles, the pH, the volume of elution solvent and the conditioning solvent, were 
evaluated and optimized by means of a univariate experimental design. 
 
Table 5 – Characteristics of the asthmatic patients and healthy individuals (controls). 
 Subjects Asthmatic 
patients 
Healthy 
individuals 
n 27 17 
Age (years; mean ± std) 8.8 ± 4.6 7.8 ± 1.4 
Gender (male:female) 16:11 10:07 
Pathology 
 
  
Allergic asthma 26 (96%) 0  
Allergic asthma + allergic rhinitis 25 (93%) 0  
Allergic asthma + sinusitis 2 (7%) 0  
Allergic asthma + conjunctivitis 7 (26%) 0  
Allergic asthma + eczema 14 (52%) 0  
Allergens 
 
  
House dust mites 19 (70%) 0  
Pollens 10 (37%) 0  
Animal epithelium 15 (56%) 0  
Moulds 3 (11%) 0  
Cockroaches 5 (19%) 0  
Initial diagnose (intermittent:mild:moderate:severe:n/aa) 6:3:12:0:4  - 
Uncontrolled asthma 27 (100%) 0  
Exacerbation in last 12 months 23 (85%) 0  
Missed school in last 12 months because of illnessb 23 (85%) 8 (47%) 
Parent/Tutor missed work in last 12 months because of the 
childb 
14 (52%) 7 (41%) 
Smoker 3 (11%) 0  
Have family members with asthma 22 (81%) 10 (59%) 
Relatives with asthma (only paternal:only maternal) 4:13 0:4 
Both relatives with asthma 5 (19%) 6 (35%) 
Without relatives with asthma 5 (19%) 7 (41%) 
a n/a – no answer. 
b Because of asthma, in the case of the asthmatic patients and because of any illness, in the case of normal 
controls. 
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The extraction efficiency of 11 commercially available MEPS sorbents including, 
C18 (octadecyl-silica), C8 (octyl-silica), C2 (ethyl-silica), SIL (silica), M1 (80% C8 + 
20% SCX – strong cation exchange), PEP (polar enhanced polymer), VAX (verify AX; 
C8 + SAX – strong anion exchange), HLB-DVB (hydrophilic-lipophilic-balanced 
reversed-phase sorbent, divinylbenzene), PGC (porous graphitic carbon), R-AX (retain 
anion exchange) and R-CX (retain cation exchange), was evaluated and optimized in 
order to select the sorbent that offers the best performance for isolation of targeted 
eicosanoids. The main characteristics of the MEPS sorbents used in this study are 
represented in Table 6. 
 The number of loading cycles was optimized by drawing up 250 µL of sample, 
3, 5 and 10 times, while the mode of the loading cycle was evaluated by drawing up the 
sample and ejecting in the same vial (extract-eject) and by drawing up the sample and 
discarding as waste (extract-discard). 
The number of loading cycles was optimized by drawing up 250 µL of sample, 3, 
5 and 10 times, while the mode of the loading cycle was evaluated by drawing up the 
sample and ejecting in the same vial (extract-eject) and by drawing up the sample and 
discarding as waste (extract-discard). 
The influence of pH was evaluated by testing the extraction efficiency at three 
different sample pH values (2.8, 5.1 and 8.5), adjusted with NaOH at 1M or FA at 10%, 
in two opposite ion exchange MEPS sorbents: R-AX and R-CX. 
Eluates were eluted into 100-µL micro-inserts (VWR International - Material de 
Laboratório, Lda., Carnaxide, Portugal), suitable for 2-mL vials. In addition, the total 
dryness of the eluate and its resuspension in 50 µL and 100 µL of mobile phase (95% 
H2O at 0.1% FA and 5% ACN at 0.1% FA) and the concentration of the eluate until half 
of its volume (without dryness) were also investigated. 
In order to investigate the best elution conditions, the impact of different elution 
solvents was investigated with different solvent solutions based on pure ACN, pure 
MeOH, acidified ACN and acidified MeOH, and different proportions of ACN and 
MeOH (50:50, 75:25 and 25:75). The washing solution, 0.1% FA, was also used to 
investigate if any of our target analytes were washed away in the washing step. After 
solvent selection, the elution volume (50 µL and 100 µL) and the number of cycles (1, 2 
and 3 times) was also investigated.
  
Table 6 – Properties of the MEPS sorbents used in this study. Adapted from Pereira et al [178]. 
Type Chemistry Name Properties and purpose 
Silica Unmodified Normal phase SIL Highly polar sorbent 
Polar analytes 
Modified Reverse phase C2 Fairly non-polar sorbent 
Analytes highly retained to C8 and C18 
C8 Non-polar sorbent 
Non-polar analytes with diverse structures 
C18 Highly non-polar sorbent 
Least selective sorbent 
Retains most organic analytes from aqueous matrices 
Analytes of diverse structures 
Functionalized Mixed-mode 
(reverse phase, ion exchange) 
M1 Dual retention mechanism 
Neutral, basic, acidic and zwitterionic analytes 
Higher selectivity for basic analytes 
VAX Non-polar and cationic sorbent 
Acidic analytes 
Moderately polar to non-polar and ionized and charged analytes 
Carbon Unmodified Reverse phase PGC Pure porous graphitic carbon material 
Highly polar compounds from different matrices 
PS-DVB Modified Reverse phase HLB-DVB Polar and non-polar sorbent 
Retain a wide spectrum of both polar and nonpolar analytes 
Functionalized Mixed-mode 
(reverse phase, ion exchange) 
PEP Urea functional groups 
Retention of polar and non-polar analytes 
Analytes of diverse structures in biological matrices 
Mixed-mode 
(normal phase, ion exchange) 
R-AX Partially functionalized sorbent with quaternary amine groups 
Balance retention of acidic and non-polar analytes 
R-CX Partially functionalized sorbent with sulfonic acidic groups 
Balance retention of basic and non-polar analytes 
Basic and neutral analytes 
Abbreviations: PS-DVB – Polymeric polystyrene – divinylbenzene, SIL – silica, C2 – ethyl-silica, C8 – octyl-silica, C18 – octadecyl-silica, M1 – mixed mode sorbent with 
80% C8 + 20% strong cation exchange, VAX – verify AX (C8 + strong anion exchange), PGC – porous graphitic carbon, HLB-DVD – hydrophilic-lipophilic-balanced reversed-
phase sorbent – DVB, PEP – polar enhanced polymer, R-AX – retain anion exchange, R-CX retain cation exchange. 
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An important step in MEPS is the conditioning of the sorbent since it can influence 
the performance of the extraction. It consists on the clean up to avoid carry-over, and 
regeneration of the active sites in the sorbent for its reuse. According to Pereira et al. 
[180], different organic solvents can be used to perform this step. In this regard, the effect 
of the conditioning solvent was performed by testing two common organic solvents, 250 
µL of ACN and 250 µL of MeOH, followed by an equilibration with 250 µL of FA at 
0.1%. The number of conditioning-equilibration cycles (1, 2 and 3 times) were tested in 
order to suppress the carry-over effect. 
In all steps of the MEPS procedure the aspiration and dispensing flow rate was 
limited to the minimum provided by the device (20 µL s-1) in order to increase the 
interaction time of the analytes with the sorbent and to minimize the occurrence of 
cavitation. All extractions were made in duplicate (n = 2). 
 
3.2.5 Chromatographic conditions. Optimization 
The analysis of the target analytes was carried out on a Waters Ultra Performance 
Liquid Chromatographic Acquity system (UPLC Acquity H-Class, Waters Corporation, 
Milford, MA, USA) equipped with a 2996 PDA detector, a Waters Acquity quaternary 
solvent manager (QSM), an Acquity sample manager, a column heater and a degassing 
system. The whole configuration was driven by Empower software v2.0 (Waters 
Corporation). In order to achieve the best performance, important instrumental 
parameters with influence on the chromatographic resolution, composition of mobile 
phase and nature of the stationary phase of capillary column, were optimized. Several 
types of columns with different dimensions including Acquity UPLC® BEH C18 
protected with an Acquity UPLC® BEH C18 VanGuard™ Pre-column, Acquity UPLC® 
HSS T3 protected with an Acquity UPLC® HSS T3 VanGuard™ Pre-column, Acquity 
UPLC® CSH C18 protected with an Acquity UPLC® CSH C18 VanGuard™ Pre-column, 
CORTECS UPLC® C18 protected with a CORTECS UPLC® C18 VanGuard™ Pre-
column, and Kinetex® HILIC protected with SecurityGuard™ ULTRA cartridge for 
HILIC UHPLC, were  evaluated in terms of peak resolution, shape and measurable areas 
of the target analytes (Table 7).
  
Table 7 – Properties of the UPLC columns used in this study. 
Chromatographic 
mode 
Name Chemistry Particle 
technology 
Particle 
size 
(µm) 
surface 
area 
(m2/g) 
pH 
range 
Pressure 
Stability 
(psi) 
Temperature 
limits (℃) 
Properties and purpose 
Low 
pH 
High 
pH 
Reversed 
phase 
Acquity 
UPLC® 
BEH C18 
C18 Fully porous 1.7 185 1 - 12 18000 80 60 Ethylene Bridged hybrid particle technology 
Universal column 
Wide variety of compounds 
Separations at high temperatures and 
extremes of pH 
Acquity 
UPLC® 
HSS T3 
Tri-
functionally 
bonded C18 
ligand 
Fully porous 1.8 230 2 - 8 18000 45 45 High strength silica particle technology 
High retention of polar organic analytes 
Balanced retention of hydrophilic and 
hydrophobic analytes 
Acquity 
UPLC® 
CSH C18 
C18 Fully porous 1.7 185 1 - 11 18000 60 45 Charged surface hybrid particle technology 
Separation of basic analytes at low pHs 
Fast pH transitions and equilibration 
Fast method development 
CORTECS 
UPLC® 
C18 
C18 Solid core 1.6 100 2 - 8 18000 45 20 Solid-core particle technology 
High efficiency and increased sensitivity 
Normal 
phase 
Kinetex® 
HILIC  
Unbonded 
silica 
(silanol 
groups) 
Solid core 
with 
a porous 
shell 
1.7 200 2 - 7.5 14500 60 < 60 Core-shell particle technology: 1.25 µm 
solid core with a 0.23 µm porous coating 
Hydrophilic interaction chromatography 
High selectivity and increased retention of 
highly polar analytes 
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These parameters were developed with spiked SU and real urine at the same 
concentration as described in a previous section. The optimized gradient was as follow: 
(A) 0.1% FA and (B) ACN acidified with FA (0.1%): 95% A (0 min), 47% A (9.5 min), 
24% A (11 min), 0% A (11.1-12.1 min) and 95% A (14 min) followed by a re-
equilibration time of 2 min. The vials containing the extracts were kept inside the sample 
manager at a temperature of 15 ℃. The flow rate was of 300 µL min-1, the injection 
volume was set at 5 µL and the capillary columns thermostatted at 30 ℃. For 
quantification purposes, the detector was set to 4 distinct channels corresponding to the 
maximum absorbance wavelength of each target analyte and IS (see Table 8). 
The identification of the target analytes was made by comparison of the retention 
time and UV-Vis spectral characteristics with those of pure standards and confirmed by 
the standard addition to the eluates. All UPLC injections were carried out in triplicate (n 
= 3). 
 
3.2.6 Method validation 
MEPS/UHPLC-PDA method was validated according to the International Union 
of Pure and Applied Chemistry (IUPAC) guidelines, being assessed the following 
parameters: selectivity, linearity, instrumental sensitivity, precision, accuracy, extraction 
efficiency and matrix effect. 
The method selectivity was assessed by analyzing the absence of interfering 
components at the retention time of the eicosanoids. 
Linearity was evaluated by spiking SU at different concentrations. A seven-point 
calibration curve for LTE4 and 11βPGF2α, and nine concentration levels for the LTB4 
were constructed from the least square linear regression model with a weighing factor of 
1/×2 by plotting the peak area ratio between each eicosanoid and the IS (Areaanalyte/AreaIS) 
against the eicosanoid concentration. Since the evaluation of the coefficient of 
determination (r2) as a measure of linearity may be misleading, the proportional ratio 
using chromatographic signal and eicosanoid concentration was confirmed by means of 
the F-test through the lack-of-fit, goodness-of-fit and Mandel’s fitting tests. 
The sensitivity of the method was expressed in terms of LOD and limit of 
quantification (LOQ). LOD is defined as the lowest concentration of analyte which can 
be reliably detectable and identified with an acceptable precision and accuracy 
(commonly within 20% RSD and within 20% bias), and LOQ is defined as the lowest 
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concentration of analyte which can be identified and quantified with a satisfactory 
precision and trueness [237]. These parameters were calculated from the least squares 
linear regression analysis being LOD defined as: a + 3.3Sa/b and LOQ as: a + 10Sa/b, 
where a represents the origin ordinate, Sa represents the standard deviation of the 
experimental value closest to the intercept, and b the slope of the calibration curve. 
The matrix effect was calculated by the ratio between the slope of the standards 
in USRU, obtained in the least squares linear regression analysis, and the slope of the 
standards in SU: 
 
Matrix effect (%) = (slopeUSRU/slopeSU)×100 
 
where slopeUSRU and slopeSU are the slopes obtained from the analytical curve of the 
USRU and SU respectively. 
In order to determine precision, accuracy and recovery percentage, the SU was 
spiked at three concentration levels corresponding to the LL, ML and high level (HL), 
covering the entire calibration range. Precision (expressed as percentage of relative 
standard deviation, % RSD) was evaluated in terms of intraday repeatability obtained 
from the analyzes of 4 replicates of spiked SU performed at the same day, and analyzed 
in the same analytical run, assayed in three different runs (n = 9) over a period of three 
days (reproducibility). 
Accuracy refers to how close the concentration values obtained experimentally 
are to the tabulated values and is calculated as follows: 
 
Accuracy (%) = (xi/x) × 100 
 
where xi represents the experimental concentration values and x the tabulated 
concentration values. This parameter was calculated with the data obtained in the least 
squares linear regression analysis. 
The recovery study allowed the evaluation of the extraction efficiency carried out 
in duplicate (n = 2) for each level of concentration. Briefly, one set of aliquots of SU was 
spiked with the analytes before the MEPS procedure and another set of unspiked SU went 
through the process and the respective eluates were spiked with the different 
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concentration levels of the target analytes. This parameter is calculated by means of the 
following formula: 
 
Recovery (%) = (SSU/SEluate) × 100 
 
where SSU represents the obtained concentration of the analytes in the spiked SU when 
added before the MEPS procedure, and SEluate represents the concentration obtained from 
the analysis of the spiked eluates. 
 
3.2.7 Statistical analysis 
Further statistical data analysis was performed by means of the IBM SPSS 
Statistics Version 22 (IBM Corp., Armonk, NY, USA). The independent samples t-test is 
used in situations with two experimental conditions with different participants in each 
condition [215]. Regarding this, the t-test was performed on the target analytes values 
obtained from the samples in order to characterize the significant differences among both 
groups under study: the asthmatic patients and normal controls, in terms of mean values. 
 
 
3.3 Results and discussion 
With this work, it was intended to develop an easy and quick analytical method 
able to detect and quantify simultaneously three eicosanoids present in urine that are 
biomarkers of inflammation and potentially of asthma per se.  
 
3.3.1 Individuals characterization 
The main characteristics of the subjects of this study are shown in Table 5. 
Family history is strongly related to asthma. Most of the asthmatic patients (81%) 
that took part of this study, had a family member with asthma being the majority (66.7%), 
maternal-related. This trend has been reported by Valerio et al. [238] where children with 
relatives with asthma are 2 to 4 times more likely to have an asthma diagnosis than 
children with no asthmatic relatives. Even though family history is strongly related to the 
asthmatic diagnosis in children, many of our asthmatic patients did not have any relative 
with asthma (19%) and many of the normal controls (59%) had a relative with an 
asthmatic diagnosis during their lifetime but no asthma or any allergen sensitization was 
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reported by this group. In the present work, it was interesting to find that most of the 
asthmatic patients were boys (59% of total population of asthmatic patients and 74% of 
asthmatic patients until 13 years old) being in accordance with the pattern of other 
countries [26]. Although the prevalence of asthma is higher in boys at this age (< 13 years 
old), the risk of developing asthma increases rapidly in women after puberty [239]. It is 
believed that these changes might have a relationship to the endocrine system, specifically 
to leptin, an hormone produced by adipocytes, related to inflammation [240] and asthma 
in children [241]. 
The main comorbidity found throughout this study was allergic rhinitis with 93% 
of the asthmatic patients with allergic asthma having also rhinitis. Although higher, this 
value is in agreement with the literature [242] which stated that allergic rhinitis coexists 
in 60 to 80% of allergic asthmatic children probably because of their similar 
pathophysiology. This comorbidity has also been found in general asthmatic population 
and not only in children but in lower values (52.3%) [243]. The most common allergen 
sensitization, among the allergic population under study, was sensitivity to house dust 
mites (70% of the allergic population) followed by animal epithelium and pollens, with 
56% and 37% respectively. A similar trend was previously reported by Boulet et al. [244]. 
 
3.3.2 MEPS optimization 
The efficiency of eleven commercial sorbents suitable for eVol®-MEPS format 
(Figure 19) was evaluated. Each sorbent has specific chemical properties that make them 
suitable for the extraction of a particular class of compounds (Table 6). As shown in 
Figure 19, R-AX was the most favorable for the isolation of all targeted eicosanoids and 
thus, was selected as the extraction sorbent for the following experiments. 
 
Figure 19 – Comparison of the efficiency of eleven commercial MEPS sorbents. Values are expressed as 
mean ± standard deviation (n = 6). 
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Although R-CX and VAX sorbents, show best efficiency for LTB4, the difference 
is not significant when compared to the overall of the R-AX that had a better extraction 
efficiency for the LTE4. Furthermore, the target analytes, 11βPGF2α, LTE4 and LTB4, 
have an acidic nature due to the presence of a carboxylic group making them suitable to 
be extracted by the R-AX. This sorbent is chemically functionalized with quaternary 
amine groups that gives to it a balanced retention capacity between acidic and non-polar 
compounds [178]. 
The number of loading cycles is determinant when developing a MEPS procedure. 
This parameter was optimized by drawing up 250 µL of sample 3, 5 and 10 times (Figure 
20A). The results showed good extraction efficiencies for the LTs, in addition to detection 
of the 11βPGF2α when the sample is drawn up and down 10 times through the sorbent. It 
has not been tested more cycles because of sorbent saturation that was reflected on 
cavitation which started to become more prominent with the increase of loading cycles 
from 5 cycles. Consequently, more time was needed for each loading cycle and thus, a 
reduction on the sorbent lifetime was expected. Additionally, the mode of the loading 
cycles was also tested. The extract-discard mode consists on the drawn up of the sample 
from an aliquot and the waste is discarded, the extract-eject mode involves the drawn-up 
of the sample from an aliquot and the waste is not discarded, returning to the aliquot. The 
extract-discard mode was selected because the obtained performance was slightly better 
(Figure 20B) for all target analytes. 
 
Figure 20 – Effect of the (A) number and (B) mode of loading cycles of the sample on the extraction 
efficiency. Values are expressed as mean ± standard deviation (n = 6). 
 
The quaternary amine groups present on the surface of the R-AX are strong bases 
with a great acid dissociation constant (pKa > 14), positively-charged at all pHs that, as 
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the name indicates, exchange or attracts anionic compounds in solution. R-CX is another 
ion exchange sorbent, functionalized with sulfonic acid groups that have very low pKa (< 
1), which make it negatively-charged at all pHs [245]. The targeted eicosanoids have low 
strongest acidic pKa (11βPGF2α = 4.36, LTE4 = 2.39 and LTB4 = 4.65; obtained from 
“The Human Metabolome Database” version 4.0 – http://www.hmdb.ca/ on November 
2017). For this reason, at a pH higher than their pKas, most of the analytes would be 
deprotonated, being able to be adsorbed through the surface of a basic sorbent. Although 
R-CX had the best results toward 11βPGF2α and in terms of total area, the extraction of 
LTE4 was not so efficient. Hence, R-AX at pH = 5.1 was chosen as the best pH for 
subsequent experiments (Figure 21). 
 
Figure 21 – Influence of the pH of the sample in the extraction efficiency with two ion exchange sorbents: 
R-AX and R-CX. Values are expressed as mean ± standard deviation (n = 6). 
 
The investigation of the eluate concentration is shown in Figure 22. 
 
Figure 22 – Influence of the eluate concentration (under N2 stream) on the extraction efficiency. 
Abbreviations: evp – evaporation; MF – mobile phase. Values are expressed as mean ± standard deviation 
(n = 6). 
 
Comparing the obtained areas from 50% evaporation of the eluates (until 50 µL) 
with the areas obtained from complete dryness and resuspension in mobile phase (50 and 
Chapter III 
 
70 
 
100 µL), it can be understood that complete dryness of the eluates is not appropriate for 
the target analytes once there are losses when resuspended. Evaporation of the eluates 
until half of its volume was the best option not only in terms of areas but also in terms of 
peak resolution and analyte detection, and therefore were used for further experiments. 
Other important steps in MEPS procedure are washing and elution. The washing 
step allows us to remove undesired matrix interferences that are weakly retained on the 
sorbent while the elution step consists on the use of the best solvent and the least volume 
possible that is able to elute the target analytes retained on the surface of the sorbent [178, 
179]. In this study, the best elution solvent was MeOH followed by ACN (Figure 23A). 
The elution volume was also considered and no substantial differences were found 
between eluting 2 or 3 times with 50 µL of MeOH (Figure 23B), therefore, in subsequent 
experiments, the elution was carried out using 2×50 µL of MeOH. The washing solvent, 
0.1% FA, was also investigated and none of the target analytes were eluted with this 
solvent making it suitable for this step (Figure 23A). 
 
Figure 23 – (A) Influence of the elution solvent and (B) volume on the extractions. Values are expressed 
as mean ± standard deviation (n = 6). 
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An important and final/beginning step of the MEPS procedure is the 
conditioning/regeneration of the fiber. Each MEPS procedure starts with the conditioning 
of the fiber with an organic solvent followed by its equilibration before the loading of the 
sample and ends with the regeneration of the fiber that match with conditioning step if 
further extractions are made [180]. Even though the best elution solvent was MeOH, it 
was remarkable to find out that ACN is a better surfactant, allowing a greater conditioning 
of the fiber (Figure 24). ACN is less viscous than MeOH (0.37 centipoise, cp versus 0.55 
cp at 20 ℃ (Physical Properties of Solvents – https://www.sigmaaldrich.com on 
November 2017) which can be a determinant factor that allows it to be more efficient 
involving the sorbent micro-particles reaching all spaces between them and consequently 
increasing the number of functionalized groups that are conditioned, improving the 
number of analytes bound to the surface of the sorbent. To the best of our knowledge, no 
previous report was made regarding the optimization of the conditioning/regeneration 
step with different solvents. To avoid carry-over, the number of conditioning-
equilibration cycles were optimized. The best results, which are the less number of cycles 
enough to remove the carry-over, was 3×250 µL of ACN - 250 µL of 0.1% FA. 
 
 
Figure 24 – Influence of the conditioning step solvent on the extraction performance. Values are expressed 
as mean ± standard deviation (n = 6). 
 
3.3.3 Optimization of chromatographic conditions 
The gradient of the mobile phase, the flow rate and several types of columns with 
different dimensions and particle sizes were tested and optimized. 
The influence of five commercial columns suitable for UPLC® analyzes were 
evaluated (Figure 25 and Figure 26A). Each column has specific chemical and physical 
properties that makes them suitable for the separation of a wide range of compounds at 
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diverse conditions (Table 7). The BEH C18 column was selected for its narrow and sharp 
peaks, reproducible retention times and good chromatographic resolution of the target 
analytes (Figure 26A) and by the areas obtained (Figure 27). This column was previously 
used by Perestrelo et al. [246] and Chappell et al. [78] for the analysis of LTs in urine and 
sputum samples. 
 
Figure 25 – Representative chromatograms of the evaluation of the different columns in synthetic urine. 
(A) CSH C18; (B) HSS T3; (C) CORTECS C18; and (D) HIILIC. Abbreviations: (1) – 11β-prostaglandin 
F2α; (2) – leukotriene E4; (3) – leukotriene B4; IS – internal standard. 
 
In terms of gradient and flow rate, the initial conditions selected were a 
modification of Perestrelo el al. [246] and were tested with spiked SU. It consisted of a 
BEH C18 column and by a gradient profile composed by (A) 0.1% FA and (B) ACN 
acidified with FA (0.1%), at a flow rate of 500 µL min-1: 95% A (0 min), 47% A (9.5 
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min), 24% A (11 min), 0% A (11.1-12.1 min) and 95% A (14 min) followed by a re-
equilibration time of 2 min. The chromatogram obtained is shown in Figure 26A. The 
best gradient with spiked SU was obtained with a flow rate of 300 µL min-1 as follows: 
95% A (0 min), 85% A (2 min), 60% A (2.5 min), 45% A (5 min); 95% A (6-7 min) 
(Figure 26B) followed by a re-equilibration time of 2 min. 
 
Figure 26 – Chromatograms obtained during gradient and flow rate optimization with a BEH C18 column 
with spiked synthetic urine samples. (A) Initial gradient at a flow rate of 500 μL min-1 as follows (A – 0.1% 
FA and B – ACN acidified with FA – 0.1%): 95% A (0 min), 47% A (9.5 min), 24% A (11 min), 0% A 
(11.1-12.1 min) and 95% A (14 min); (B) Optimized gradient at a flow rate of 300 μL min-1 as follows: 
95% A (0 min), 85% A (2 min), 60% A (2.5 min), 45% A (5 min); 95% A (6-7 min). Abbreviations: (1) – 
11β-prostaglandin F2α; (2) – leukotriene E4; (3) – leukotriene B4; IS – internal standard. 
 
The best conditions obtained with SU were tested using spiked real urine. As 
shown in Figure 28A, these conditions were not effective once the analytes were co-eluted 
with urine interferents. A modification of the initial conditions in terms of flow rate (300 
µL min-1) were successfully tested with spiked real urine (Figure 28B) and spiked SU 
(Figure 29). With this optimization, even though we were not able to reduce the run time 
of analysis, a considerable decrease of 40% on the amount of solvent was achieved which 
is important regarding environmental issues and cost of analysis. Regarding the gradient 
of the mobile phase and the flow rate, they were optimized for the best results within a 
total run time of 16 min, including column equilibration. A representative chromatogram 
obtained with the final optimized conditions in SU is shown in Figure 29. 
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Figure 27 – Influence of five commercial columns suitable for UPLC® analyzes. Values are expressed as 
mean ± standard deviation (n = 3). 
 
Considering the obtained data, the best chromatographic conditions were obtained 
using a gradient elution mode, with a flow rate of 300 µL min-1, as follows: 95% A (0 
min), 47% A (9.5 min), 24% A (11 min), 0% A (11.1-12.1 min) and 95% A (14 min) 
followed by a re-equilibration time of 2 min using an UHPLC-PDA equipped with a BEH 
C18 capillary column. 
 
Figure 28 – Chromatograms obtained during gradient and flow rate optimization with a BEH C18 column 
with spiked real urine. (A) Best gradient and flow rate obtained with spiked synthetic urine samples applied 
to spiked real urine; (B) Optimized gradient in spiked real urine samples at a flow rate of 300 μL min-1 as 
follows: 95% A (0 min), 47% A (9.5 min), 24% A (11 min), 0% A (11.1-12.1 min) and 95% A (14 min). 
Abbreviations: (1) – 11β-prostaglandin F2α; (2) – leukotriene E4; (3) – leukotriene B4; IS – internal standard. 
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3.3.4 Method validation 
In order to demonstrate the practicability of the developed analytical strategy and 
its ability to quantify the target analytes in urine samples, the method was fully validated 
in terms of selectivity, linearity, instrumental sensitivity, precision, accuracy, extraction 
efficiency and matrix effect for each eicosanoid. The method figures of merit are 
described in Table 8 and Table 9. 
 
Table 8 – Analytical performance of the optimized methodology. 
Analytes IS 11βPGF2α LTE4 LTB4 
Peak number - 1 2 3 
RTa (min) 7.43 7.65 9.61 10.75 
λmaxb (nm) 366 192 281 270 
LDRc (ng mL -1) - 5 - 300 0.5 - 30 0.1 - 30 
Calibration in solvent        
Regression equation - y = 0.1304x + 0.6418 y = 0.1225x + 0.0627 y = 0.1708x + 0.0105 
r2d - 0.9988 0.9989 0.9997 
re - 0.9994 0.9995 0.9998 
Calibration in matrix         
Regression equation - y = 0.0951x - 2.6893 y = 0.0932x + 0.0224 y = 0.1385x - 0.0640 
r2d - 0.9841 0.9884 0.9989 
re - 0.9920 0.9942 0.9994 
Matrix effect (%) - 73 76 81 
Sensitivity         
LODf (ng mL-1) - 1.12 0.16 0.04 
LOQg (ng mL-1) - 2.11 0.35 0.10 
Lack-of-fit test         
Fcalculated:Ftabulatedh - 1.48:2.49h 0.67:2.49h 0.32:2.22i 
Goodness-of-fit test         
Fcalculated:Ftabulated - 0.00:2.49h 0.06:2.49h 0.11:2.22i 
Mandel's fitting test         
Fcalculated:Ftabulated - 2.50:7.71j 0.12:7.71j 0.08:5.99k 
a RT – retention time. 
b λmax – maximum absorbance values obtained in the PDA system detection. 
c LDR – linear dynamic range. 
d r2 – coefficient of determination. 
e r – coefficient of correlation (Person’s r). 
f LOD – limit of detection. 
g LOQ – limit of quantification. 
h Ftabulated – numerator degrees of freedom (df1) = 5; denominator degrees of freedom (df2) = 35; p = 95%. 
i Ftabulated – df1 = 7; df2 = 45; p = 95%. 
j Ftabulated – df1 = 1; df2 = 4; p = 95%. 
k Ftabulated – df1 = 1; df2 = 6; p = 95%. 
 
Selectivity was demonstrated by the absence of interfering peaks at the retention 
times of the target analytes in blank SU. Figure 29 clearly demonstrates the absence of 
interfering peaks in the retention times demonstrating the ability of the analytical method 
to unequivocally identify and quantify the analytes of interest. 
 
Chapter III 
 
76 
 
Table 9 – Precision, accuracy and extraction efficiency obtained for the 11β-prostaglandin F2α (11βPGF2α), 
leukotriene E4 (LTE4) and leukotriene B4 (LTB4) at different levels of concentration. 
Analytes Level of 
concentrationa 
(ng mL-1) 
Precision (%) Accuracy 
(%) 
Extraction 
efficiency Intraday 
repeatability 
Intermediate 
precision 
11βPGF2α LL 25 3.17 4.81 93.62 95.52 
  ML 100 3.17 3.89 100.50 99.71 
  HL 200 3.73 5.40 103.02 98.87 
LTE4 LL 2.5 6.63 10.43 96.73 91.13 
  ML 10 4.70 2.86 95.85 83.86 
  HL 20 3.11 1.29 103.51 74.99 
LTB4 LL 2.5 6.17 6.54 101.08 84.53 
  ML 10 4.82 3.57 96.32 92.25 
  HL 20 4.58 3.68 100.04 88.14 
a Levels of concentration in the validation studies: LL – low level, ML – medium level and HL – high 
level. 
 
The linearity was assayed using different calibration curves of each analyte 
obtained by least squares linear regression analysis as described in section 3.1.6 Method 
validation. All of three regression equations of the target analytes showed a coefficient 
of determination higher than 0.9980 but these values alone, do not guarantee the linearity 
of the signal. Therefore, linearity was assessed by means of the F-test at different 
approaches: lack-of-fit test, based on the analysis of the residual variance; goodness-of-
fit test, based on the ratio between the mean sum of squares of the factors and the 
residuals; and Mandel’s fitting test, based on the difference between the residual standard 
deviation of the obtained first-order calibration model and a potential second-order 
calibration model,  as described by Kruve et al. [139]. The signal is considered linear 
when the calculated F, by means of the experimental data, is lower than the respective 
tabulated F. As show in Table 8, all signal linearities (Lack-of-fit, Godness-of-fit and 
Mandel’s tests) calculated by the previous mentioned approaches, are confirmed (Fcalculated 
< Ftabulated) with a 95% confidence level. 
The sensitivity can be described as the lowest value of concentration at which the 
method is able to detect (LOD) and quantify (LOQ) the target analytes (Table 8) with 
satisfactory accuracy and precision. As previously reported, the developed method 
showed low values of LOD which ranged between 0.04 ng mL-1 for LTB4 and 1.12 ng 
mL-1 for 11βPGF2α while LOQ values ranged between 0.10 ng mL-1 for the LTB4 and 
2.11 ng mL-1 for 11βPGF2α. 
Matrix effect was also evaluated in order to determine which calibration curve 
should be used during the real sample analysis. The values obtained with this test is 
represented in Table 8. All the target analytes have revealed considerable matrix effects 
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with 73% for the 11βPGF2α, 76% for the LTE4 and 81% for the LTB4. Consequently, the 
regression equation obtained with real urine would be used for further real sample 
analyzes. 
 
Figure 29 – Representative chromatograms of an unspiked synthetic urine and synthetic urine spiked with 
the investigated standards: (1) 11β-prostaglandin F2α, (2) leukotriene E4 and (3) leukotriene B4 – at the best 
optimization parameters obtained at (A) 192 nm and (B) 281 nm. 
 
An important parameter when validating a method is precision. This parameter 
can be defined as repeatability at which the % RSD is calculated in order to assess the 
error associated between replicates performed in the same day, and as reproducibility at 
which the % RSD is calculated in order to assess the error associated between replicates 
performed over a certain period of days. The developed method proved to have 
repeatability with values that ranged from 3.11% for LTE4 at HL and 6.63% at LL for the 
same analyte. As for reproducibility, values ranged from 1.29% for LTE4 at HL and 
10.43% at LL for the same compound being LTE4 on the extremes of both precision 
approaches (Table 9). 
The performance of the method can also be assayed as accuracy. In general, all 
experimental values have shown to be accurate (approximately 100%) during the study 
of this parameter with less than 7% deviation from the tabulated value as shown in Table 
9. The least accurate was 11βPGF2α at LL with 93.62%, and LTB4 the most accurate with 
100.04%. 
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The extraction efficiency was evaluated in order to know how much of the target 
analytes is lost during extractions. The obtained recovery percentage for 11βPGF2α 
ranged between 95.52% at a LL and 99.71% at a ML; LTE4 ranged between 74.99% and 
91.13% at HL and LL respectively; and LTB4 ranged from 84.53% at LL and 92.25% at 
ML (Table 9). 
 
3.3.5 Stability of the extracts 
The stability of the extracts was tested with the target analytes at different 
concentrations (LL and ML), over a 24-hour period with analyzes running each 8 hours. 
It was found out that eluates were stable for 8 hours, with less than 6% lost during 
the tested time, but after that time, the LTs stability decrease, being the 11βPGF2α the 
most stable with less than 7% lost during the assay as observed in Figure 30. All the 
analyzes were performed taking into account the stability of the extracts. 
 
Figure 30 – Stability of extracts at 0, 8, 16 and 24 hours after extraction. Target analytes were at low level 
(LL) and medium level (ML) of concentration. 
 
3.3.6 Application of the developed MEPS/UHPLC-PDA methodology 
In order to evaluate the applicability of the method to urine samples, R-AX sorbent 
and the developed method proposed in this study were applied to detect the three 
eicosanoids – 11βPGF2α, LTE4 and LTB4, in urine of 27 asthmatic and 17 healthy 
children. The concentration values obtained for the urine of each asthmatic patient and 
healthy individual (control) is represented in the Table 2A, Annex VIII. Figure 31 
represents a chromatogram of an asthmatic patient and another from a normal control. 
Even though these eicosanoids are at a very low concentration, in a complex matrix, it is 
clear the difference on peaks intensity between controls and asthmatic groups. 
One third of the normal controls had values bellow the limit of quantification or 
detection, except for the 11βPGF2α that was not detected in 2 asthmatic patients. In both 
groups, the major analyte was 11βPGF2α with greater values when compared to the two 
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LTs of this study. 11βPGF2α values varied from bellow the LOD (< LOD) until 310.32 ± 
9.59 ng mL-1 for the asthmatic patients group, and from 32.16 ± 1.00 until 167.29 ± 17.75 
ng mL-1 for the normal controls. LTE4 values varied from < LOD until 4.94 ± 0.22 ng 
mL-1 for the asthmatic group, and from 0.47 ± 0.06 until 2.53 ± 0.41 ng mL-1 for the 
normal controls. The trend for the LTB4 was the same with values between < LOD and 
2.64 ± 0.05 ng mL-1 for asthmatics and < LOD and 1.74 ± 0.05 ng mL-1 for normal 
controls. 
 
Figure 31 – Representative chromatograms of urine from a healthy individual (CTRL) and urine from an 
asthmatic patient (ASMT) at (A) 192, (B) 281, and (C) 270 nm. Numbers represent the target analytes: (1) 
11β-prostaglandin F2α, (2) leukotriene E4 and (3) leukotriene B4. Boxes on the up-right corner of each 
chromatogram represent the magnification of the target analyte peak. 
 
Before running the t-test some specific assumptions were evaluated, including the 
type of the variables, independence of observations, normal distribution, outliers and 
homogeneity of variances [215]. The results showed that there are significant differences 
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between groups. For this procedure, the logarithmic values of concentrations were used 
in order to obtain values closer to the normal pattern. For the 11βPGF2α, the t-test value 
was 7.415 with 289.6 degrees of freedom (df; p < 0.001); the LTE4 had a t-test value of 
3.653 (df = 217, p < 0.001) and LTB4 had 5.437 (df = 198, p < 0.001). The mean values 
calculated by means of the t-test procedure of each target analyte and investigated group, 
are shown in Table 2A, Annex VIII. 
PGD2 is a major COX metabolite produced during an inflammatory response by 
mast cells and leukocytes as dendritic cells and Th2 cells with a pro-inflammatory role. 
This unstable eicosanoid is rapidly transformed into more stable products, PGs of the J 
series and 11βPGF2α [77]. As PGD2, 11βPGF2α also has biological activity as 
bronchoconstrictor and contraction of coronary arteries [247], and can be found in 
increased values in the urine of asthmatic patients after allergen-induced  
bronchoconstriction [227] and after exercise challenge [81]. On average, the asthmatic 
patients had higher concentrations of 11βPGF2α (112.96 ng mL-1) than normal controls 
(62.56 ng mL-1; Figure 32) with a mean difference of about 50.40 ng mL-1 between 
groups. This significant difference (p < 0.001) represent a medium-sized effect (r = 0.40). 
The difference among the total population was between 35.97 and 64.83 ng mL-1 for this 
eicosanoid, with a confidence level of 95%. 
 
Figure 32 – 11β-prostaglandin F2α (11βPGF2α), leukotriene E4 (LTE4) and leukotriene B4 (LTB4) mean 
concentrations obtained for the urine of asthmatic patients and urine of healthy individuals. 
 
Cys-LTs, powerful bronchoconstrictors, 100 to 1000 times more powerful than 
histamine [59], play an important role in the pathophysiology of asthma. They also have 
a role in the vascular permeability allowing the exudation of inflammatory cells from 
plasma to the airway mucosa, stimulate mucus secretion and inhibit mucociliar clearance 
– characteristics of the pathophysiology of asthma [59]. Since LTC4 and LTD4 are 
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biologically converted into LTE4, they are not excreted in measurable concentrations in 
urine. Therefore, LTE4 is considered a biomarker of the total of cys-LTs levels in urine 
[72]. Studies suggest that LTE4 is dependent on allergen dose inhaled during allergen 
challenge in asthmatic patients [66]. Having this into account, in the evaluation of the 
groups present in this study, it was found increased mean levels of LTE4 in the urine of 
asthmatic patients with 1.27 ng mL-1 against 0.89 ng mL-1 in normal controls (Figure 32) 
with a mean difference of 0.38 ng mL-1. This difference was significant (p < 0.001) and 
represented a small-sized effect (r = 0.24). Regarding the total population, the difference 
was of 0.11-0.64 ng mL-1 with a confidence level of 95%. 
LTB4 is produced by a diversity of cells including neutrophils and macrophages 
and it is a powerful pro-inflammatory chemoattractant whose main targets are neutrophils 
promoting their activation, adhesion to the endothelium and chemotaxis. This LT also 
activates neutrophils degranulation of additional mediators and it is also involved in 
inflammatory pain by neutrophils dependent processes [59]. LTB4 tend to be in higher 
concentrations in diverse matrices like EBC [248], sputum [249] and urine [246]. The 
asthmatic patients of our investigations had a trend for higher values of LTB4 with a mean 
concentration of 1.39 ng mL-1 in the urine of asthmatics patients against 0.76 ng mL-1 in 
the normal controls (Figure 32; mean difference = 0.63 ng mL-1). This difference was 
significant (p < 0.001) and represented a medium-sized effect (r = 0.36). In terms of total 
population, the difference varied between 0.47 and 0.78 ng mL-1 with a confidence level 
of 95%. 
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Throughout this work, it was developed a powerful methodology able to 
simultaneously detect and quantify eicosanoid asthma biomarkers present in urine of 
asthmatic patients and healthy individuals. 
During the development of the method, eleven commercial sorbents with different 
chemical properties were evaluated with SU. The number of sample loading cycles as 
well as their mode (extract-discard and extract-eject) were tested. Three different sample 
pHs were studied (acid pH, physiological pH and basic pH) with two ion exchange 
sorbents (R-AX and R-CX). The elution was studied in terms of solvents, based on ACN 
and MeOH (pure and acidified), and volume. The conditioning solvent (MeOH and ACN) 
was also evaluated and optimized in terms of extraction efficiency. In addition, the 
influence of eluate concentration under N2 stream was investigated. The best extraction 
conditions for the targeted analytes were obtained using R-AX as sorbent, 3 conditioning-
equilibration cycles with 250 μL of ACN-H2O at 0.1% FA, 10 extract-discard cycles of 
250 μL of sample at a pH of 5.1, an elution with 2 times 50 μL of MeOH and the 
concentration of the eluate until half of initial volume. 
In terms of chromatographic conditions, a set of five commercial capillary 
columns with different dimensions and stationary phases were evaluated and optimized. 
BEH C18 proved to be the best column in terms of peak resolution, shape and measurable 
areas for the targeted analytes. The gradient and flow rate of mobile phase were also 
evaluated. The optimized gradient of mobile phase, for both SU and real urine, was 
obtained with 0.1% FA and ACN acidified with FA (0.1%) with a run time of 14 min at 
a flow rate of 300 μL min-1 followed by a re-equilibration of 2 min. 
The validation of the method revealed compatible values for each parameter in 
SU. The selectivity evaluation reveled no interfering peaks at the retention times of the 
target analytes. All signals proved to be linear by means of the three different fitting tests 
(lack-of-fit, goodness-of-fit and Mandel’s fitting tests). The instrumental sensitivity 
showed low values of LOD (0.04 ng mL-1 for LTB4 and 1.12 ng mL-1 for 11βPGF2α) and 
LOQ (0.10 ng mL-1 for the LTB4 and 2.11 ng mL-1 for 11βPGF2α). The developed method 
revealed to be precise in terms of repeatability (3.11% for LTE4 at HL and 6.63% at LL 
for the same analyte) and reproducibility (1.29% for LTE4 at HL and 10.43% at LL for 
the same analyte); accurate, with less than 7% of deviation from the tabulated value; and 
efficient (> 74.99%). All targeted analytes revealed matrix effect. The extracts were 
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analyzed within a period of 8 hours since the stability test revealed they were stable for 
this period of time. 
Therefore, it was possible to successfully apply the method to the samples and 
discriminate between asthmatics and healthy individuals. On average, the urine of 
asthmatic patients presented significantly higher concentrations of all eicosanoids. The 
obtained values for the 11βPGF2α and LTB4 were about 1.8 times higher and for the LTE4 
were about 1.4 times higher in asthmatic patients than in healthy individuals. 
The developed MEPS/UHPLC-PDA approach proved to be an ultra-fast, accurate, 
precise and easy analytical strategy. The extraction procedure is fast (a total analysis time 
of 31 min). Furthermore, The MEPS/UHPLC-PDA procedure revealed to be 
environmental friendly due to the reduce levels of solvents consumed during both 
extraction and analytical procedures. 
The developed MEPS/UHPLC-PDA method reveled to be a promising strategy 
regarding the study of these and other eicosanoids present in other biological matrices 
such as plasma, sputum and EBC of patients from inflammatory illnesses other than 
asthma. 
The results obtained during the experimental work suggest the potential of these 
eicosanoids on asthma diagnosis. However, a larger and more extensive study would be 
necessary, using a bigger number of cases, to confirm the data obtained, guarantee a 
greater robustness to the approach and to obtain a stratification of the patients in terms of 
age, level of control (well-controlled, partly controlled and uncontrolled) and their 
therapeutic response using the developed method. 
In the future,  I would also be interested in learning other extractive or 
chromatographic techniques as well as I would like to continue in the health field studying 
other diseases. 
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Annex I – Composition of the synthetic urine 
 
Table 1A – Composition of the synthetic urine used during the optimization and validation of the method. 
Name Formula g L-1 
Calcium chloride-2-hydrate CaCl2·2H2O 0.65 
Magnesium chloride-6-hydrate MgCl2·6H2O 0.65 
Sodium chloride NaCl 4.60 
Sodium sulfate anhydrous Na2SO4 2.30 
tri-Sodium citrate-2-hydrate Na3C6H5O7·2H2O 0.65 
Sodium carbonate anhydrous Na2CO3 0.02 
Potassium di-hydrogen phosphate KH2PO4 4.20 
Potassium chloride KCl 1.60 
Ammonium chloride NH4Cl 1.00 
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Annex II – SESARAM authorization 
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Annex III – DRE authorization 
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Annex IV – Information to the subject of investigation 
 
 
 
 
Projecto: VOM_ASM 
Informação ao Sujeito de Investigação 
Por favor, leia com atenção a informação referente à explicação do projeto. Se achar que algo está 
incorreto ou que não está claro, não hesite em solicitar mais informações.  
 
Responsáveis pelo projecto 
Prof. Dr. José Sousa Câmara; Centro de Química da Madeira (CQM/UMa); Faculdade de Ciências Exatas e da 
Engenharia da Universidade da Madeira 
Telefone: 351-291705112 Fax : 351-291705149 Email: jsc@uma.pt 
Drª. Susana Oliveira; Hospital Dr. Nélio Mendonça, SESARAM, E.P.E.; Avenida Luís de Camões, nº 57 – 9004-514 
Funchal 
Título do estudo: 
IMPLEMENTAÇÃO DE NOVA ABORDAGEM METODOLÓGICA PARA A DETEÇÃO DE 
BIOMARCADORES DE DOENÇAS RESPIRATÓRIAS DE NATUREZA ALÉRGICA.  
A ASMA COMO CASO DE ESTUDO 
 
Pretende-se desenvolver uma metodologia analítica que permita a identificação de 
biomarcadores associados a patologias respiratórias de natureza alérgica. Este estudo objectiva 
estabelecer as bases metodológicas e químicas que permitam contribuir para o 
desenvolvimento de um meio de diagnóstico rápido, barato e não invasivo, que possa ser 
aplicado a um número alargado de indivíduos, mesmo numa fase assintomática, assim como 
para monitorizar a evolução dos efeitos terapêuticos. 
Para tal precisamos da colaboração voluntária do Vosso Educando no estudo, que se traduz na 
cedência de amostras de urina (jato médio) e saliva, que serão recolhidas no Hospital Dr. Nélio 
Mendonça aquando da consulta de rotina e/ou entrada / internamento médico. Esta recolha 
será supervisionada por um técnico de saúde sob a coordenação da Drª Susana Oliveira. 
Solicitamos igualmente a colaboração voluntária dos Pais/Encarregados de 
Educação/representante legal para a recolha das amostras, caso seja necessário. 
Aos sujeitos, que voluntariamente participarem no estudo, não serão impostas quaisquer 
restrições alimentares ou de outro tipo, apenas será importante o preenchimento de um 
pequeno formulário inquérito. 
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O estudo não acarretará riscos ou encargos para os participantes. Não haverá qualquer tipo de 
contacto do Investigador com o sujeito dador. 
O estudo tem o parecer favorável da Comissão de Ética para a Saúde do (CES) do Serviço 
Regional de Saúde. 
 
Confidencialidade e anonimato: As amostras serão codificadas pelos responsáveis, e só eles 
terão acesso ao binómio código / indivíduo, garantindo desta forma a máxima 
confidencialidade e anonimato dos resultados.  
 
Agradecidos desde já pela V. atenção  
 
Prof. Dr. José Sousa Câmara 
Investigador e Professor Auxiliar na Universidade da Madeira,  
Centro de Química da Madeira (CQM/UMa); Faculdade de Ciências Exatas e Engenharia da Universidade 
da Madeira 
Telefone: 351-291705112   Fax : 351-291705149    
Email: jsc@uma.pt 
 
Drª. Susana Oliveira 
Serviço de Alergologia do Hospital Dr. Nélio Mendonça,  
SESARAM, E.P.E.; Avenida Luís de Camões, nº 57 – 904-514 Funchal 
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Annex V – Informed consent 
 
 
 
 
IMPLEMENTAÇÃO DE NOVA ABORDAGEM METODOLÓGICA PARA A DETEÇÃO DE 
BIOMARCADORES DE DOENÇAS RESPIRATÓRIAS DE NATUREZA ALÉRGICA.  
A ASMA COMO CASO DE ESTUDO 
 
Projecto: VOM_ASM 
 
Consentimento Informado Livre e Esclarecido para Participação em Investigação  
de acordo com a Declaração de Helsínquia e a Convenção de Oviedo 
 
Por favor, leia com atenção a folha de informação referente à explicação do projeto. Se achar que algo 
está incorreto ou que não está claro, não hesite em solicitar mais informações. Se concorda em participar 
ou se permite a participação do seu educando de forma voluntária no estudo queira assinar este 
documento. 
 
 
Eu, ______________________________________________________________, 
declaro que após a leitura e compreensão do documento de Informação 
referente à pesquisa e objetivos do projeto VOM-ASM, autorizo voluntariamente 
o meu educando a participar no estudo com a cedência de amostras de urina e 
saliva e autorizo o processamento e a publicação anónima e confidencial dos 
dados/resultados obtidos. Mais informo que me é facultada a possibilidade de 
desistência de participação no estudo em qualquer momento. 
 
 
Funchal, ______ de _____________________ de 201__ 
 
 
O Investigador O Declarante/Sujeito 
__________________________ ______________________  
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Annex VI – Questionnaire for asthmatic patients from hospital 
 
 
 
 
Projecto: VOM_ASM 
Formulário de inquérito  
 
Data de preenchimento: ___/___/______ 
Instituição:  Nº amostra:  
 
Este questionário destina-se exclusivamente à recolha de dados de investigação para a elaboração do 
projeto “IMPLEMENTAÇÃO DE NOVA ABORDAGEM METODOLÓGICA PARA A DETEÇÃO DE 
BIOMARCADORES DE DOENÇAS RESPIRATÓRIAS DE NATUREZA ALÉRGICA. A ASMA COMO CASO 
DE ESTUDO”. 
Os dados recolhidos são confidenciais. A veracidade das respostas é de importância crucial na elaboração 
do estudo. 
Caso tenha alguma dúvida nas questões, peça esclarecimento ao Técnico de Saúde presente. 
Agradecemos desde já pela atenção e colaboração, 
José Sousa Câmara (Universidade da Madeira) 
Drª. Susana Oliveira (Hospital Dr. Nélio Mendonça) 
 
Dados Pessoais: 
Idade: Sexo:     M         F   
 
Informações gerais acerca de saúde e hábitos de consumo do sujeito  
Sim Não 
Estado actual Totalmente 
Controlado 
Parcialmente 
controlado 
Não controlado 
Diagnóstico com base na gravidade Intermitente Persistente 
ligeira 
Persistente 
moderada 
Persistente 
severa 
Teve algum ataque de asma nos últimos 12 meses?   
Data da última crise asmática 201_/__/__ 
Faltou à escola devido a problemas de asma nos últimos 12 
meses? 
  
O Encarregado de Educação faltou ao trabalho devido a 
problemas de asma do educando? 
  
Tem conjuntivite alérgica   
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Tem alguma alergia nasal? 
  
Já lhe foi diagnosticada rinite alérgica? 
  
Já lhe foi diagnosticado sinusite? 
  
Já lhe foi diagnosticado bronquite? 
  
Já teve alergias na pele ou eczema? 
  
Sensibilizações  
É fumador?   
Quantos membros da sua residência são fumadores? 
 
Quantos cigarros (em média) fumam por dia?  
Tipo de habitação.  
Quantos quartos tem a sua habitação?  
Quantas pessoas vivem na sua habitação?  
Na sua habitação possui esquentador a gás?   
Dentro ou fora de casa?  
Na sua habitação possui cozinha/churrascaria a lenha?   
Possui chaminé?   
Vive perto de algum sítio que liberte poeiras ou fumos?   
Que sítio?  
Tem familiares com asma?   
Quem?  
Toma medicação para a asma (ex. inaladores ou outros)? 
  
Qual? __________________ 
____________________________________________________________________ 
Com que frequência (tomas diárias)? 1 2 ≥3 
Naturalidade __________________ 
 
 
 
Número do processo clínico __________________ 
Médico __________________ 
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Annex VII – Questionnaire for healthy individuals from 
schools 
 
 
 
 
Projecto: VOM_ASM 
Amostra__________________ 
 
Qual é o nome da tua escola? ______________________________________________ 
Qual é o teu número de aluno? ________________________ 
Sexo: Masculino ☐ ou Feminino ☐ 
Quantos anos tens? __________ 
És natural de onde? ________________________ 
Data ________________________ 
 
 Sim  Não 
Alguma vez disseram que tinhas asma?      
    
 Sim  Não 
Costumas ter falta de ar por causa de alergias?      
    
 Sim  Não 
Costumas ter pieira por causa de alergias?      
    
 Sim  Não 
Costumas ter tosse por causa de alergias?      
    
 Sim  Não 
Tiveste algum ataque de asma durante o último ano?      
    
 Sim  Não 
Faltaste à escola ou outras actividades durante o último ano?      
    
 Sim  Não 
O teu pai, a tua mãe ou a pessoa que cuida de ti      
faltaram ao trabalho por tua causa?    
    
Lê com atenção as perguntas. Se tiveres alguma dúvida pergunta aos teus pais 
ou ao teu professor. 
Por favor assinala com um X a resposta que descreve melhor a pergunta. 
Algumas perguntas tens de colocar um número. 
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 Sim  Não 
Costumas ter comichão ou irritação nos olhos por causa de alergias?          
 Sim  Não 
Costumas ter comichão no nariz ou na garganta por causa de alergias?          
 Sim  Não 
Costumas espirrar por causa de alergias?      
    
 Sim  Não 
Costumas ter ranho ou o nariz a pingar por causa de alergias?          
 Sim  Não 
Costumas ter a pele irritada, vermelha, seca,       
com borbulhas ou a escamar por causa de alguma alergia?        
 Sim  Não 
Tens alergia ao pó, poeira?          
 Sim  Não 
Tens alergia ao pêlo de animais?          
 Sim  Não 
Tens alergia ao pólen ou a flores?          
 Sim  Não 
Tens alergia a baratas ou outros insectos?          
 
Quantas pessoas vivem contigo?      
    
Alguma(s) das pessoas com quem vives fuma(m)? Quantas?          
    
Quantos cigarros fuma(m)/dia (mais ou menos)?          
 Casa  Apa 
Vives numa casa ou apartamento (Apa)?              
 Sim  Não 
Tens esquentador em casa?          
 Sim  Não 
O teu esquentador é a gás?          
 Sim  Não 
O teu esquentador fica dentro de casa?          
 Sim  Não 
Tens alguma cozinha a lenha ou churrascaria em casa?          
 Sim  Não 
E tem chaminé?          
 Sim  Não 
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Há alguma oficina de carros que faça fumo perto da tua casa?          
 Sim  Não 
Há algum sítio perto da tua casa onde trabalhem       
com madeira ou pedra e faça poeira?        
        
 Sim  Não 
O teu pai ou alguém da família da parte do teu pai tem asma?          
 Sim  Não 
A tua mãe ou alguém da família da parte da tua mãe tem asma?          
 Sim  Não 
Tomas remédios para a asma ou as tuas alergias?          
 1  2  3 
Quantas vezes por dia?      
    
    
O que é que tomas para a asma ou para as tuas alergias?  
_____________________________________________________________________________ 
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Annex VIII – Concentration of the eicosanoids obtained for the 
urine of asthmatic patients and healthy individuals 
 
Table 2A – Levels (ng mL-1) of 11β-prostaglandin F2α (11βPGF2α), leukotriene E4 (LTE4) and leukotriene 
B4 (LTB4) determined in urine of asthmatic patients and healthy individuals (control group). 
Sample 11βPGF2α
a 
(ng mL-1) 
LTE4b 
(ng mL-1) 
LTB4c 
(ng mL-1) 
Asthmatics    
1 48.71 ± 1.06 0.92 ± 0.07 1.62 ± 0.07 
2 44.62 ± 8.57 2.80 ± 0.10 2.14 ± 0.05 
3 47.05 ± 6.78 < LODd 1.27 ± 0.05 
4 34.99 ± 2.70 1.60 ± 0.32 1.00 ± 0.01 
5 103.65 ± 13.25 3.12 ± 0.25 1.07 ± 0.04 
6 310.32 ± 9.59 3.27 ± 0.23 2.64 ± 0.05 
7 99.25 ± 8.53 < LODd < LODd 
8 < LODd < LODd 1.42 ± 0.07 
9 292.41 ± 13.51 1.41 ± 0.21 1.88 ± 0.11 
10 173.12 ± 21.64 1.81 ± 0.08 2.22 ± 0.07 
11 178.50 ± 21.06 0.94 ± 0.07 1.95 ± 0.07 
12 69.84 ± 2.06 2.34 ± 0.14 0.90 ± 0.01 
13 181.01 ± 38.03 < LOQe 1.81 ± 0.03 
14 37.26 ± 1.56 1.44 ± 0.14 0.73 ± 0.04 
15 32.39 ± 0.63 1.06 ± 0.22 1.79 ± 0.14 
16 212.98 ± 33.85 < LODd 1.31 ± 0.22 
17 30.84 ± 0.79 1.70 ± 0.08 2.42 ± 0.21 
18 108.05 ± 14.69 3.52 ± 0.42 1.91 ± 0.13 
19 56.45 ± 4.28 0.52 ± 0.04 < LODd 
20 80.28 ± 2.82 < LODd 0.60 ± 0.02 
21 38.83 ± 1.70 < LODd < LODd 
22 < LODd < LOQe 1.12 ± 0.05 
23 170.71 ± 1.25 0.78 ± 0.03 0.77 ± 0.01 
24 106.20 ± 2.10 1.18 ± 0.27 2.58 ± 0.04 
25 121.05 ± 5.46 0.43 ± 0.06 1.27 ± 0.05 
26 302.29 ± 15.99 4.94 ± 0.22 1.65 ± 0.08 
27 139.89 ± 5.52 0.42 ± 0.03 1.40 ± 0.04 
Mean 112.96f 1.27f 1.39f 
Healthy    
1 113.60 ± 5.71 < LOQe < LODd 
2 38.09 ± 0.41 0.58 ± 0.06 1.25 ± 0.16 
3 35.82 ± 0.99 0.74 ± 0.13 < LODd 
4 32.16 ± 1.00 0.56 ± 0.08 < LODd 
5 45.68 ± 1.76 < LOQe 1.29 ± 0.05 
6 167.29 ± 17.75 < LODd 1.20 ± 0.08 
7 41.84 ± 4.41 1.94 ± 0.19 1.57 ± 0.07 
8 47.59 ± 1.88 < LODd 0.76 ± 0.04 
9 51.32 ± 1.36 2.31 ± 0.20 0.70 ± 0.04 
10 58.79 ± 1.86 1.98 ± 0.26 1.74 ± 0.05 
11 50.38 ± 5.26 0.71 ± 0.08 < LODd 
12 102.27 ± 7.67 0.47 ± 0.06 0.82 ± 0.05 
13 33.79 ± 1.43 < LOQe 1.03 ± 0.07 
14 66.70 ± 0.84 1.59 ± 0.13 < LODd 
15 38.77 ± 7.32 2.53 ± 0.41 1.46 ± 0.19 
16 54.09 ± 6.52 0.57 ± 0.03 1.12 ± 0.10 
17 85.38 ± 6.91 1.00 ± 0.17 < LODd 
Mean 62.56f 0.89f 0.76g 
a 11βPGF2α – 11β-Prostaglandin F2α 
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b LTE4 – Leukotriene E4 
c LTB4 – Leukotriene B4 
d LOD – limit of detection. 
e LOQ – limit of quantification. 
Means followed by different letters (f and g) for a given parameter are significantly different at p < 0.001 
(independent samples t-test).
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
  
 
  
 
